JP2014523888A - フッ素化アリールアルキルアミノカルボキサミド誘導体 - Google Patents
フッ素化アリールアルキルアミノカルボキサミド誘導体 Download PDFInfo
- Publication number
- JP2014523888A JP2014523888A JP2014517549A JP2014517549A JP2014523888A JP 2014523888 A JP2014523888 A JP 2014523888A JP 2014517549 A JP2014517549 A JP 2014517549A JP 2014517549 A JP2014517549 A JP 2014517549A JP 2014523888 A JP2014523888 A JP 2014523888A
- Authority
- JP
- Japan
- Prior art keywords
- ethylamino
- difluoro
- butoxyphenyl
- phenyl
- acetamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000011734 sodium Substances 0.000 claims abstract description 44
- 108010052164 Sodium Channels Proteins 0.000 claims abstract description 39
- 102000018674 Sodium Channels Human genes 0.000 claims abstract description 39
- 102000003922 Calcium Channels Human genes 0.000 claims abstract description 35
- 108090000312 Calcium Channels Proteins 0.000 claims abstract description 35
- 229910052708 sodium Inorganic materials 0.000 claims abstract description 33
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims abstract description 32
- 150000003839 salts Chemical class 0.000 claims abstract description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 230000000926 neurological effect Effects 0.000 claims abstract description 11
- 230000002526 effect on cardiovascular system Effects 0.000 claims abstract description 7
- 239000004480 active ingredient Substances 0.000 claims abstract description 6
- 150000001875 compounds Chemical class 0.000 claims description 148
- 229910052739 hydrogen Inorganic materials 0.000 claims description 73
- 239000001257 hydrogen Substances 0.000 claims description 73
- 239000003814 drug Substances 0.000 claims description 66
- 238000011282 treatment Methods 0.000 claims description 63
- 208000002193 Pain Diseases 0.000 claims description 62
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 58
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 54
- 229940079593 drug Drugs 0.000 claims description 49
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 47
- 239000000203 mixture Substances 0.000 claims description 47
- 208000035475 disorder Diseases 0.000 claims description 41
- 238000000034 method Methods 0.000 claims description 39
- -1 3-butoxyphenyl Chemical group 0.000 claims description 37
- 108010001237 Cytochrome P-450 CYP2D6 Proteins 0.000 claims description 33
- 102100021704 Cytochrome P450 2D6 Human genes 0.000 claims description 33
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 33
- 125000001153 fluoro group Chemical group F* 0.000 claims description 23
- 208000004296 neuralgia Diseases 0.000 claims description 23
- 208000021722 neuropathic pain Diseases 0.000 claims description 22
- 125000003386 piperidinyl group Chemical group 0.000 claims description 21
- 125000005843 halogen group Chemical group 0.000 claims description 19
- 125000004193 piperazinyl group Chemical group 0.000 claims description 19
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 18
- 230000004054 inflammatory process Effects 0.000 claims description 16
- 125000002757 morpholinyl group Chemical group 0.000 claims description 16
- BDKGQYCBHDRFHX-UHFFFAOYSA-N 2-[[2,2-difluoro-2-[3-(4,4,4-trifluorobutoxy)phenyl]ethyl]amino]-1-(4-methylpiperazin-1-yl)ethanone Chemical compound C1CN(C)CCN1C(=O)CNCC(F)(F)C1=CC=CC(OCCCC(F)(F)F)=C1 BDKGQYCBHDRFHX-UHFFFAOYSA-N 0.000 claims description 15
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 15
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 14
- 230000001419 dependent effect Effects 0.000 claims description 14
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 14
- 201000010099 disease Diseases 0.000 claims description 13
- 239000000126 substance Substances 0.000 claims description 13
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims description 12
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 12
- 230000003287 optical effect Effects 0.000 claims description 12
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 10
- 208000000094 Chronic Pain Diseases 0.000 claims description 10
- 206010010904 Convulsion Diseases 0.000 claims description 10
- 206010015037 epilepsy Diseases 0.000 claims description 10
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 10
- 206010019233 Headaches Diseases 0.000 claims description 9
- 108010053752 Voltage-Gated Sodium Channels Proteins 0.000 claims description 9
- 102000016913 Voltage-Gated Sodium Channels Human genes 0.000 claims description 9
- 125000000217 alkyl group Chemical group 0.000 claims description 9
- 208000010877 cognitive disease Diseases 0.000 claims description 9
- 230000004064 dysfunction Effects 0.000 claims description 9
- 231100000869 headache Toxicity 0.000 claims description 9
- 208000020016 psychiatric disease Diseases 0.000 claims description 9
- 208000005298 acute pain Diseases 0.000 claims description 8
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 8
- 125000000335 thiazolyl group Chemical group 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 7
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 7
- 208000030814 Eating disease Diseases 0.000 claims description 6
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000002393 azetidinyl group Chemical group 0.000 claims description 6
- 235000014632 disordered eating Nutrition 0.000 claims description 6
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 6
- 208000019423 liver disease Diseases 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 6
- 125000004076 pyridyl group Chemical group 0.000 claims description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
- 230000028327 secretion Effects 0.000 claims description 6
- SODKQGQSPZPDCL-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]-methylamino]-n,n-dimethylacetamide Chemical compound CCCCOC1=CC=CC(C(F)(F)CN(C)CC(=O)N(C)C)=C1 SODKQGQSPZPDCL-UHFFFAOYSA-N 0.000 claims description 5
- FIKWZVSDABRZSL-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-n,n-dimethylacetamide Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N(C)C)=C1 FIKWZVSDABRZSL-UHFFFAOYSA-N 0.000 claims description 5
- 208000028698 Cognitive impairment Diseases 0.000 claims description 5
- 208000007220 Cytochrome P-450 CYP2D6 Inhibitors Diseases 0.000 claims description 5
- 208000017701 Endocrine disease Diseases 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 229940124597 therapeutic agent Drugs 0.000 claims description 5
- SXYKINBAZCLVRK-UHFFFAOYSA-N 2-[[2,2-difluoro-2-[3-(4,4,4-trifluorobutoxy)phenyl]ethyl]amino]-1-pyrrolidin-1-ylethanone Chemical compound FC(F)(F)CCCOC1=CC=CC(C(F)(F)CNCC(=O)N2CCCC2)=C1 SXYKINBAZCLVRK-UHFFFAOYSA-N 0.000 claims description 4
- 208000009205 Tinnitus Diseases 0.000 claims description 4
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 claims description 4
- 230000009885 systemic effect Effects 0.000 claims description 4
- 231100000886 tinnitus Toxicity 0.000 claims description 4
- FAORHTSMLOXMEC-UHFFFAOYSA-N 1-[4-(benzenesulfonyl)piperazin-1-yl]-2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]ethanone Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N2CCN(CC2)S(=O)(=O)C=2C=CC=CC=2)=C1 FAORHTSMLOXMEC-UHFFFAOYSA-N 0.000 claims description 3
- RCEMPTYZFWREQA-UHFFFAOYSA-N 2-[[2,2-difluoro-2-[3-(4,4,4-trifluorobutoxy)phenyl]ethyl]amino]-1-piperidin-1-ylethanone Chemical compound FC(F)(F)CCCOC1=CC=CC(C(F)(F)CNCC(=O)N2CCCCC2)=C1 RCEMPTYZFWREQA-UHFFFAOYSA-N 0.000 claims description 3
- HRGOBOHTYLYXPP-UHFFFAOYSA-N 2-[[2,2-difluoro-2-[3-[3-(1,3-thiazol-2-yl)propoxy]phenyl]ethyl]amino]-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CNCC(F)(F)C1=CC=CC(OCCCC=2SC=CN=2)=C1 HRGOBOHTYLYXPP-UHFFFAOYSA-N 0.000 claims description 3
- AXLFCEWENZWCGJ-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-3-methoxy-n,n-dimethylpropanamide Chemical compound CCCCOC1=CC=CC(C(F)(F)CNC(COC)C(=O)N(C)C)=C1 AXLFCEWENZWCGJ-UHFFFAOYSA-N 0.000 claims description 3
- HAYJINKVXZMRFS-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-n,n-dimethylpropanamide Chemical compound CCCCOC1=CC=CC(C(F)(F)CNC(C)C(=O)N(C)C)=C1 HAYJINKVXZMRFS-UHFFFAOYSA-N 0.000 claims description 3
- 208000005392 Spasm Diseases 0.000 claims description 3
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims description 3
- 230000001149 cognitive effect Effects 0.000 claims description 3
- 125000006222 dimethylaminomethyl group Chemical group [H]C([H])([H])N(C([H])([H])[H])C([H])([H])* 0.000 claims description 3
- 208000002173 dizziness Diseases 0.000 claims description 3
- 125000002541 furyl group Chemical group 0.000 claims description 3
- 125000001544 thienyl group Chemical group 0.000 claims description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- ZGFFBTBJDSFFLK-UHFFFAOYSA-N 1-(4-benzylpiperazin-1-yl)-2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]ethanone Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N2CCN(CC=3C=CC=CC=3)CC2)=C1 ZGFFBTBJDSFFLK-UHFFFAOYSA-N 0.000 claims description 2
- BFCLZSYJJXMEQX-UHFFFAOYSA-N 1-(azetidin-1-yl)-2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]ethanone Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N2CCC2)=C1 BFCLZSYJJXMEQX-UHFFFAOYSA-N 0.000 claims description 2
- KKTIULIVDVFECB-UHFFFAOYSA-N 2-[[2,2-difluoro-2-(3-hexoxyphenyl)ethyl]amino]-n,n-dimethylacetamide Chemical compound CCCCCCOC1=CC=CC(C(F)(F)CNCC(=O)N(C)C)=C1 KKTIULIVDVFECB-UHFFFAOYSA-N 0.000 claims description 2
- QHVUHIZNVVKGDQ-UHFFFAOYSA-N 2-[[2,2-difluoro-2-(3-pentoxyphenyl)ethyl]amino]-n,n-dimethylacetamide Chemical compound CCCCCOC1=CC=CC(C(F)(F)CNCC(=O)N(C)C)=C1 QHVUHIZNVVKGDQ-UHFFFAOYSA-N 0.000 claims description 2
- SHEGTFSJPQZGFO-UHFFFAOYSA-N 2-[[2,2-difluoro-2-(3-pentoxyphenyl)ethyl]amino]-n,n-dipropylacetamide Chemical compound CCCCCOC1=CC=CC(C(F)(F)CNCC(=O)N(CCC)CCC)=C1 SHEGTFSJPQZGFO-UHFFFAOYSA-N 0.000 claims description 2
- QLFGQTFLECQFNG-UHFFFAOYSA-N 2-[[2,2-difluoro-2-(3-phenylmethoxyphenyl)ethyl]amino]-1-morpholin-4-ylethanone Chemical compound C=1C=CC(OCC=2C=CC=CC=2)=CC=1C(F)(F)CNCC(=O)N1CCOCC1 QLFGQTFLECQFNG-UHFFFAOYSA-N 0.000 claims description 2
- CTQYVVFHKWJMJI-UHFFFAOYSA-N 2-[[2,2-difluoro-2-(3-phenylmethoxyphenyl)ethyl]amino]-1-piperidin-1-ylethanone Chemical compound C=1C=CC(OCC=2C=CC=CC=2)=CC=1C(F)(F)CNCC(=O)N1CCCCC1 CTQYVVFHKWJMJI-UHFFFAOYSA-N 0.000 claims description 2
- XCCBIGWHHCMXSF-UHFFFAOYSA-N 2-[[2,2-difluoro-2-(3-phenylmethoxyphenyl)ethyl]amino]-1-pyrrolidin-1-ylethanone Chemical compound C=1C=CC(OCC=2C=CC=CC=2)=CC=1C(F)(F)CNCC(=O)N1CCCC1 XCCBIGWHHCMXSF-UHFFFAOYSA-N 0.000 claims description 2
- OWKULWIAAHYFTD-UHFFFAOYSA-N 2-[[2,2-difluoro-2-(3-phenylmethoxyphenyl)ethyl]amino]-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CNCC(F)(F)C1=CC=CC(OCC=2C=CC=CC=2)=C1 OWKULWIAAHYFTD-UHFFFAOYSA-N 0.000 claims description 2
- KMWRMIPWRJRUFR-UHFFFAOYSA-N 2-[[2,2-difluoro-2-[3-(3-phenylpropoxy)phenyl]ethyl]amino]-1-(4-methylpiperazin-1-yl)ethanone Chemical compound C1CN(C)CCN1C(=O)CNCC(F)(F)C1=CC=CC(OCCCC=2C=CC=CC=2)=C1 KMWRMIPWRJRUFR-UHFFFAOYSA-N 0.000 claims description 2
- IVEURWHKKDQOBM-UHFFFAOYSA-N 2-[[2,2-difluoro-2-[3-(3-phenylpropoxy)phenyl]ethyl]amino]-1-morpholin-4-ylethanone Chemical compound C=1C=CC(OCCCC=2C=CC=CC=2)=CC=1C(F)(F)CNCC(=O)N1CCOCC1 IVEURWHKKDQOBM-UHFFFAOYSA-N 0.000 claims description 2
- GFPCVELQKPZWRY-UHFFFAOYSA-N 2-[[2,2-difluoro-2-[3-(3-phenylpropoxy)phenyl]ethyl]amino]-1-piperidin-1-ylethanone Chemical compound C=1C=CC(OCCCC=2C=CC=CC=2)=CC=1C(F)(F)CNCC(=O)N1CCCCC1 GFPCVELQKPZWRY-UHFFFAOYSA-N 0.000 claims description 2
- GUAZREBBGUSCSR-UHFFFAOYSA-N 2-[[2,2-difluoro-2-[3-(3-phenylpropoxy)phenyl]ethyl]amino]-1-pyrrolidin-1-ylethanone Chemical compound C=1C=CC(OCCCC=2C=CC=CC=2)=CC=1C(F)(F)CNCC(=O)N1CCCC1 GUAZREBBGUSCSR-UHFFFAOYSA-N 0.000 claims description 2
- FAAXVXZYEKYQQH-UHFFFAOYSA-N 2-[[2,2-difluoro-2-[3-(3-phenylpropoxy)phenyl]ethyl]amino]-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CNCC(F)(F)C1=CC=CC(OCCCC=2C=CC=CC=2)=C1 FAAXVXZYEKYQQH-UHFFFAOYSA-N 0.000 claims description 2
- QQZYMQMTIIYZCL-UHFFFAOYSA-N 2-[[2,2-difluoro-2-[3-(3-phenylpropoxy)phenyl]ethyl]amino]-n-methyl-n-phenylacetamide Chemical compound C=1C=CC=CC=1N(C)C(=O)CNCC(F)(F)C(C=1)=CC=CC=1OCCCC1=CC=CC=C1 QQZYMQMTIIYZCL-UHFFFAOYSA-N 0.000 claims description 2
- GXGAFUDRXBZNIL-UHFFFAOYSA-N 2-[[2,2-difluoro-2-[3-(4,4,4-trifluorobutoxy)phenyl]ethyl]amino]-1-morpholin-4-ylethanone Chemical compound FC(F)(F)CCCOC1=CC=CC(C(F)(F)CNCC(=O)N2CCOCC2)=C1 GXGAFUDRXBZNIL-UHFFFAOYSA-N 0.000 claims description 2
- WTWQPFYYFFQRKN-UHFFFAOYSA-N 2-[[2,2-difluoro-2-[3-(4,4,4-trifluorobutoxy)phenyl]ethyl]amino]-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CNCC(F)(F)C1=CC=CC(OCCCC(F)(F)F)=C1 WTWQPFYYFFQRKN-UHFFFAOYSA-N 0.000 claims description 2
- VIKGAKSHMJHQQE-UHFFFAOYSA-N 2-[[2,2-difluoro-2-[3-(4,4,4-trifluorobutoxy)phenyl]ethyl]amino]-n-methyl-n-phenylacetamide Chemical compound C=1C=CC=CC=1N(C)C(=O)CNCC(F)(F)C1=CC=CC(OCCCC(F)(F)F)=C1 VIKGAKSHMJHQQE-UHFFFAOYSA-N 0.000 claims description 2
- KRQFAOLTELBSFH-UHFFFAOYSA-N 2-[[2,2-difluoro-2-[3-[(2-fluorophenyl)methoxy]phenyl]ethyl]amino]-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CNCC(F)(F)C1=CC=CC(OCC=2C(=CC=CC=2)F)=C1 KRQFAOLTELBSFH-UHFFFAOYSA-N 0.000 claims description 2
- ACFYWLHWDUBDEK-UHFFFAOYSA-N 2-[[2,2-difluoro-2-[3-[3-(3-fluorophenyl)propoxy]phenyl]ethyl]amino]-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CNCC(F)(F)C1=CC=CC(OCCCC=2C=C(F)C=CC=2)=C1 ACFYWLHWDUBDEK-UHFFFAOYSA-N 0.000 claims description 2
- KMTAVNUMYRRGSU-UHFFFAOYSA-N 2-[[2-(3-butoxy-2-fluorophenyl)-2,2-difluoroethyl]amino]-n,n-dimethylacetamide Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N(C)C)=C1F KMTAVNUMYRRGSU-UHFFFAOYSA-N 0.000 claims description 2
- AOBHEKNCMKJUMM-UHFFFAOYSA-N 2-[[2-(3-butoxy-4-methylphenyl)-2,2-difluoroethyl]amino]-n,n-dimethylacetamide Chemical compound CCCCOC1=CC(C(F)(F)CNCC(=O)N(C)C)=CC=C1C AOBHEKNCMKJUMM-UHFFFAOYSA-N 0.000 claims description 2
- QCVFELWQJLUVRQ-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]-(2-methoxyethyl)amino]-n,n-dimethylacetamide Chemical compound CCCCOC1=CC=CC(C(F)(F)CN(CCOC)CC(=O)N(C)C)=C1 QCVFELWQJLUVRQ-UHFFFAOYSA-N 0.000 claims description 2
- UTJKBMBIMFSVGN-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]-(3-methoxypropyl)amino]-n,n-dimethylacetamide Chemical compound CCCCOC1=CC=CC(C(F)(F)CN(CCCOC)CC(=O)N(C)C)=C1 UTJKBMBIMFSVGN-UHFFFAOYSA-N 0.000 claims description 2
- HBFVXWZWDMJGIF-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-1-(2,3-dihydro-1,4-benzoxazin-4-yl)ethanone Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N2C3=CC=CC=C3OCC2)=C1 HBFVXWZWDMJGIF-UHFFFAOYSA-N 0.000 claims description 2
- XVZIGZABZAVPBW-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-1-(2,3-dihydroindol-1-yl)ethanone Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N2C3=CC=CC=C3CC2)=C1 XVZIGZABZAVPBW-UHFFFAOYSA-N 0.000 claims description 2
- MPQJDWCZZJBZEE-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-1-(3,4-dihydro-1h-isoquinolin-2-yl)ethanone Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N2CC3=CC=CC=C3CC2)=C1 MPQJDWCZZJBZEE-UHFFFAOYSA-N 0.000 claims description 2
- VMRTWUHEIIMBAI-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-1-(4-methylpiperazin-1-yl)ethanone Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N2CCN(C)CC2)=C1 VMRTWUHEIIMBAI-UHFFFAOYSA-N 0.000 claims description 2
- KVCMWDKTFVFKHH-CALCHBBNSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-1-[(3r,5s)-3,5-dimethylpiperidin-1-yl]ethanone Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N2C[C@H](C)C[C@H](C)C2)=C1 KVCMWDKTFVFKHH-CALCHBBNSA-N 0.000 claims description 2
- RLNUZVOPYFZQKR-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-1-piperidin-1-ylethanone Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N2CCCCC2)=C1 RLNUZVOPYFZQKR-UHFFFAOYSA-N 0.000 claims description 2
- AHBUYLAFSYCLIB-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-1-pyrrolidin-1-ylethanone Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N2CCCC2)=C1 AHBUYLAFSYCLIB-UHFFFAOYSA-N 0.000 claims description 2
- ZKGMNDVMFYWCMK-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-3-(4-methoxyphenyl)-n,n-dimethylpropanamide Chemical compound CCCCOC1=CC=CC(C(F)(F)CNC(CC=2C=CC(OC)=CC=2)C(=O)N(C)C)=C1 ZKGMNDVMFYWCMK-UHFFFAOYSA-N 0.000 claims description 2
- NBIZZDZZEGSYRL-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-n,n-di(propan-2-yl)acetamide Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N(C(C)C)C(C)C)=C1 NBIZZDZZEGSYRL-UHFFFAOYSA-N 0.000 claims description 2
- ZAGMODBFWVMCQK-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-n,n-dibutylacetamide Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N(CCCC)CCCC)=C1 ZAGMODBFWVMCQK-UHFFFAOYSA-N 0.000 claims description 2
- OXOMBDGCDDHRAY-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-n,n-dipropylacetamide Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N(CCC)CCC)=C1 OXOMBDGCDDHRAY-UHFFFAOYSA-N 0.000 claims description 2
- KYVVKTXXZVCKKG-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-n-cyclohexyl-n-methylacetamide Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N(C)C2CCCCC2)=C1 KYVVKTXXZVCKKG-UHFFFAOYSA-N 0.000 claims description 2
- UCJQJAOTMPHXIG-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-n-methyl-n-phenylacetamide Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N(C)C=2C=CC=CC=2)=C1 UCJQJAOTMPHXIG-UHFFFAOYSA-N 0.000 claims description 2
- KSCUKCRDTBCWIF-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2-fluoroethyl]amino]-n,n-dimethylacetamide Chemical compound CCCCOC1=CC=CC(C(F)CNCC(=O)N(C)C)=C1 KSCUKCRDTBCWIF-UHFFFAOYSA-N 0.000 claims description 2
- VCZSXRROGQWWJO-UHFFFAOYSA-N 2-[[2-[3-[(3-chlorophenyl)methoxy]phenyl]-2-fluoroethyl]amino]-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CNCC(F)C1=CC=CC(OCC=2C=C(Cl)C=CC=2)=C1 VCZSXRROGQWWJO-UHFFFAOYSA-N 0.000 claims description 2
- GKCPYUSKJUAUAZ-UHFFFAOYSA-N 2-[[2-[3-[3-(3-chlorophenyl)propoxy]phenyl]-2,2-difluoroethyl]amino]-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CNCC(F)(F)C1=CC=CC(OCCCC=2C=C(Cl)C=CC=2)=C1 GKCPYUSKJUAUAZ-UHFFFAOYSA-N 0.000 claims description 2
- FIKIGUMINMMKJD-UHFFFAOYSA-N 2-[[2-fluoro-2-[3-[(3-fluorophenyl)methoxy]phenyl]ethyl]amino]-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CNCC(F)C1=CC=CC(OCC=2C=C(F)C=CC=2)=C1 FIKIGUMINMMKJD-UHFFFAOYSA-N 0.000 claims description 2
- 208000007101 Muscle Cramp Diseases 0.000 claims description 2
- 230000036461 convulsion Effects 0.000 claims description 2
- 230000018448 secretion by cell Effects 0.000 claims description 2
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 2
- MLCYIAIOTNYMPQ-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-n,n-diethylacetamide Chemical compound CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N(CC)CC)=C1 MLCYIAIOTNYMPQ-UHFFFAOYSA-N 0.000 claims 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 abstract description 11
- 230000002265 prevention Effects 0.000 abstract description 11
- 230000007246 mechanism Effects 0.000 abstract description 8
- 230000002757 inflammatory effect Effects 0.000 abstract description 6
- 208000014001 urinary system disease Diseases 0.000 abstract description 5
- 208000018522 Gastrointestinal disease Diseases 0.000 abstract description 4
- 230000007170 pathology Effects 0.000 abstract description 4
- 208000012931 Urologic disease Diseases 0.000 abstract description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 69
- 238000012360 testing method Methods 0.000 description 50
- 239000000243 solution Substances 0.000 description 47
- 230000036407 pain Effects 0.000 description 42
- 210000004027 cell Anatomy 0.000 description 37
- 230000004044 response Effects 0.000 description 33
- 230000000694 effects Effects 0.000 description 30
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 28
- 108091006146 Channels Proteins 0.000 description 26
- 241000700159 Rattus Species 0.000 description 26
- 229940083542 sodium Drugs 0.000 description 25
- 238000006243 chemical reaction Methods 0.000 description 24
- 235000015424 sodium Nutrition 0.000 description 24
- 238000005160 1H NMR spectroscopy Methods 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 21
- 230000005764 inhibitory process Effects 0.000 description 21
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 18
- 241001465754 Metazoa Species 0.000 description 18
- 239000011575 calcium Substances 0.000 description 17
- 229940127291 Calcium channel antagonist Drugs 0.000 description 16
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 16
- 102000004190 Enzymes Human genes 0.000 description 16
- 108090000790 Enzymes Proteins 0.000 description 16
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 16
- 229960004397 cyclophosphamide Drugs 0.000 description 16
- 229940088598 enzyme Drugs 0.000 description 16
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- 108090000699 N-Type Calcium Channels Proteins 0.000 description 15
- 102000004129 N-Type Calcium Channels Human genes 0.000 description 15
- 229910052791 calcium Inorganic materials 0.000 description 15
- 235000001465 calcium Nutrition 0.000 description 15
- 239000000480 calcium channel blocker Substances 0.000 description 15
- 230000002401 inhibitory effect Effects 0.000 description 15
- 229960003920 cocaine Drugs 0.000 description 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 14
- 239000003112 inhibitor Substances 0.000 description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- 210000004556 brain Anatomy 0.000 description 13
- 230000000638 stimulation Effects 0.000 description 13
- 239000003480 eluent Substances 0.000 description 12
- 241000282414 Homo sapiens Species 0.000 description 11
- 230000001684 chronic effect Effects 0.000 description 11
- 210000002569 neuron Anatomy 0.000 description 11
- 230000000284 resting effect Effects 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 101000654386 Homo sapiens Sodium channel protein type 9 subunit alpha Proteins 0.000 description 10
- 230000006870 function Effects 0.000 description 10
- 239000012528 membrane Substances 0.000 description 10
- 208000004454 Hyperalgesia Diseases 0.000 description 9
- 206010061218 Inflammation Diseases 0.000 description 9
- 208000006011 Stroke Diseases 0.000 description 9
- 210000003050 axon Anatomy 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 9
- 238000002347 injection Methods 0.000 description 9
- 239000007924 injection Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- 239000003981 vehicle Substances 0.000 description 9
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 239000001961 anticonvulsive agent Substances 0.000 description 8
- 238000003556 assay Methods 0.000 description 8
- 238000003818 flash chromatography Methods 0.000 description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 239000003208 petroleum Substances 0.000 description 8
- 201000000980 schizophrenia Diseases 0.000 description 8
- 239000003195 sodium channel blocking agent Substances 0.000 description 8
- CFMYXEVWODSLAX-UHFFFAOYSA-N tetrodotoxin Natural products C12C(O)NC(=N)NC2(C2O)C(O)C3C(CO)(O)C1OC2(O)O3 CFMYXEVWODSLAX-UHFFFAOYSA-N 0.000 description 8
- KWTSXDURSIMDCE-QMMMGPOBSA-N (S)-amphetamine Chemical compound C[C@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-QMMMGPOBSA-N 0.000 description 7
- 208000020925 Bipolar disease Diseases 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 7
- 101000684820 Homo sapiens Sodium channel protein type 3 subunit alpha Proteins 0.000 description 7
- 208000019695 Migraine disease Diseases 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 7
- 235000011054 acetic acid Nutrition 0.000 description 7
- 230000003542 behavioural effect Effects 0.000 description 7
- 239000012267 brine Substances 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 230000002779 inactivation Effects 0.000 description 7
- 230000001537 neural effect Effects 0.000 description 7
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 210000003594 spinal ganglia Anatomy 0.000 description 7
- 239000000758 substrate Substances 0.000 description 7
- CFMYXEVWODSLAX-QOZOJKKESA-N tetrodotoxin Chemical compound O([C@@]([C@H]1O)(O)O[C@H]2[C@@]3(O)CO)[C@H]3[C@@H](O)[C@]11[C@H]2[C@@H](O)N=C(N)N1 CFMYXEVWODSLAX-QOZOJKKESA-N 0.000 description 7
- 229950010357 tetrodotoxin Drugs 0.000 description 7
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 6
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- 101000654356 Homo sapiens Sodium channel protein type 10 subunit alpha Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 102100023720 Sodium channel protein type 3 subunit alpha Human genes 0.000 description 6
- 102100031367 Sodium channel protein type 9 subunit alpha Human genes 0.000 description 6
- 208000027418 Wounds and injury Diseases 0.000 description 6
- 230000001154 acute effect Effects 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 125000000623 heterocyclic group Chemical group 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 230000006742 locomotor activity Effects 0.000 description 6
- 206010027599 migraine Diseases 0.000 description 6
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 229910000104 sodium hydride Inorganic materials 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000001356 surgical procedure Methods 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 102100028728 Bone morphogenetic protein 1 Human genes 0.000 description 5
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
- 206010026749 Mania Diseases 0.000 description 5
- 206010070834 Sensitisation Diseases 0.000 description 5
- 229930006000 Sucrose Natural products 0.000 description 5
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 5
- 206010046543 Urinary incontinence Diseases 0.000 description 5
- 229960004782 chlordiazepoxide Drugs 0.000 description 5
- 206010009887 colitis Diseases 0.000 description 5
- 210000003618 cortical neuron Anatomy 0.000 description 5
- 201000006549 dyspepsia Diseases 0.000 description 5
- 210000003414 extremity Anatomy 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 239000003589 local anesthetic agent Substances 0.000 description 5
- 230000033001 locomotion Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 230000028161 membrane depolarization Effects 0.000 description 5
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 5
- 230000035772 mutation Effects 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 5
- 230000002093 peripheral effect Effects 0.000 description 5
- 230000002085 persistent effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 230000008313 sensitization Effects 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 229960004793 sucrose Drugs 0.000 description 5
- 230000002459 sustained effect Effects 0.000 description 5
- 208000011580 syndromic disease Diseases 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 230000009184 walking Effects 0.000 description 5
- CNIIGCLFLJGOGP-UHFFFAOYSA-N 2-(1-naphthalenylmethyl)-4,5-dihydro-1H-imidazole Chemical compound C=1C=CC2=CC=CC=C2C=1CC1=NCCN1 CNIIGCLFLJGOGP-UHFFFAOYSA-N 0.000 description 4
- PVRCSKCAERGTQG-UHFFFAOYSA-N 2-(3-butoxyphenyl)acetonitrile Chemical compound CCCCOC1=CC=CC(CC#N)=C1 PVRCSKCAERGTQG-UHFFFAOYSA-N 0.000 description 4
- IEOUEWOHAFNQCO-UHFFFAOYSA-N 2-(3-hydroxyphenyl)acetonitrile Chemical compound OC1=CC=CC(CC#N)=C1 IEOUEWOHAFNQCO-UHFFFAOYSA-N 0.000 description 4
- LXKNAUOWEJWGTE-UHFFFAOYSA-N 2-(3-methoxyphenyl)acetonitrile Chemical compound COC1=CC=CC(CC#N)=C1 LXKNAUOWEJWGTE-UHFFFAOYSA-N 0.000 description 4
- 206010002091 Anaesthesia Diseases 0.000 description 4
- 208000019901 Anxiety disease Diseases 0.000 description 4
- 201000006474 Brain Ischemia Diseases 0.000 description 4
- 206010008120 Cerebral ischaemia Diseases 0.000 description 4
- ILIKEJWOTBNRLO-UHFFFAOYSA-N Cl.FC(CNC(C(=O)N(C)C)C)(C1=CC(=CC=C1)OCCCC)F Chemical compound Cl.FC(CNC(C(=O)N(C)C)C)(C1=CC(=CC=C1)OCCCC)F ILIKEJWOTBNRLO-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 4
- 208000010412 Glaucoma Diseases 0.000 description 4
- 101000631760 Homo sapiens Sodium channel protein type 1 subunit alpha Proteins 0.000 description 4
- 101000640020 Homo sapiens Sodium channel protein type 11 subunit alpha Proteins 0.000 description 4
- 206010020751 Hypersensitivity Diseases 0.000 description 4
- 206010020853 Hypertonic bladder Diseases 0.000 description 4
- 206010065390 Inflammatory pain Diseases 0.000 description 4
- 102000004310 Ion Channels Human genes 0.000 description 4
- 108090000862 Ion Channels Proteins 0.000 description 4
- 208000028389 Nerve injury Diseases 0.000 description 4
- 208000009722 Overactive Urinary Bladder Diseases 0.000 description 4
- 239000004698 Polyethylene Substances 0.000 description 4
- 102100028910 Sodium channel protein type 1 subunit alpha Human genes 0.000 description 4
- 102100031374 Sodium channel protein type 10 subunit alpha Human genes 0.000 description 4
- HUCJFAOMUPXHDK-UHFFFAOYSA-N Xylometazoline Chemical compound CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCCN1 HUCJFAOMUPXHDK-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 229940025084 amphetamine Drugs 0.000 description 4
- 230000037005 anaesthesia Effects 0.000 description 4
- 238000000540 analysis of variance Methods 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 4
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 4
- 229960000623 carbamazepine Drugs 0.000 description 4
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 4
- 206010008118 cerebral infarction Diseases 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 239000003638 chemical reducing agent Substances 0.000 description 4
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 4
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 230000002999 depolarising effect Effects 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000004941 influx Effects 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 229960005015 local anesthetics Drugs 0.000 description 4
- 210000003141 lower extremity Anatomy 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 229940127237 mood stabilizer Drugs 0.000 description 4
- 239000004050 mood stabilizer Substances 0.000 description 4
- 230000008764 nerve damage Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- 201000008482 osteoarthritis Diseases 0.000 description 4
- 208000020629 overactive bladder Diseases 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 210000001044 sensory neuron Anatomy 0.000 description 4
- GZKLJWGUPQBVJQ-UHFFFAOYSA-N sertindole Chemical compound C1=CC(F)=CC=C1N1C2=CC=C(Cl)C=C2C(C2CCN(CCN3C(NCC3)=O)CC2)=C1 GZKLJWGUPQBVJQ-UHFFFAOYSA-N 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 3
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 3
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 3
- PRNVHVUEIITLRV-UHFFFAOYSA-N 7-chloro-4-hydroxy-n-methyl-5-phenyl-3h-1,4-benzodiazepin-2-imine;hydron;chloride Chemical compound Cl.C=12C=C(Cl)C=CC2=NC(=NC)CN(O)C=1C1=CC=CC=C1 PRNVHVUEIITLRV-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 208000008035 Back Pain Diseases 0.000 description 3
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 3
- 0 Cc1cc(C(*)(*)C#N)ccc1 Chemical compound Cc1cc(C(*)(*)C#N)ccc1 0.000 description 3
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 3
- 206010012735 Diarrhoea Diseases 0.000 description 3
- 208000005171 Dysmenorrhea Diseases 0.000 description 3
- 206010013935 Dysmenorrhoea Diseases 0.000 description 3
- 239000012981 Hank's balanced salt solution Substances 0.000 description 3
- 206010019196 Head injury Diseases 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000896576 Homo sapiens Putative cytochrome P450 2D7 Proteins 0.000 description 3
- 101000654381 Homo sapiens Sodium channel protein type 8 subunit alpha Proteins 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 208000028017 Psychotic disease Diseases 0.000 description 3
- 102100021702 Putative cytochrome P450 2D7 Human genes 0.000 description 3
- 241000700157 Rattus norvegicus Species 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 102100033974 Sodium channel protein type 11 subunit alpha Human genes 0.000 description 3
- 102100031371 Sodium channel protein type 8 subunit alpha Human genes 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 208000025865 Ulcer Diseases 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 208000026935 allergic disease Diseases 0.000 description 3
- 230000007815 allergy Effects 0.000 description 3
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 230000003556 anti-epileptic effect Effects 0.000 description 3
- 239000003416 antiarrhythmic agent Substances 0.000 description 3
- 229960003965 antiepileptics Drugs 0.000 description 3
- 230000036506 anxiety Effects 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 230000000903 blocking effect Effects 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 230000003727 cerebral blood flow Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 3
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 229960000632 dexamfetamine Drugs 0.000 description 3
- 235000013681 dietary sucrose Nutrition 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 239000000975 dye Substances 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 238000010304 firing Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000002496 gastric effect Effects 0.000 description 3
- 125000002883 imidazolyl group Chemical group 0.000 description 3
- 208000026278 immune system disease Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 3
- PYZRQGJRPPTADH-UHFFFAOYSA-N lamotrigine Chemical compound NC1=NC(N)=NN=C1C1=CC=CC(Cl)=C1Cl PYZRQGJRPPTADH-UHFFFAOYSA-N 0.000 description 3
- 229960001848 lamotrigine Drugs 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 201000006417 multiple sclerosis Diseases 0.000 description 3
- 210000004165 myocardium Anatomy 0.000 description 3
- RLKHFSNWQCZBDC-UHFFFAOYSA-N n-(benzenesulfonyl)-n-fluorobenzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)N(F)S(=O)(=O)C1=CC=CC=C1 RLKHFSNWQCZBDC-UHFFFAOYSA-N 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 229960001412 pentobarbital Drugs 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 125000006239 protecting group Chemical group 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 229960001534 risperidone Drugs 0.000 description 3
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 description 3
- 229960000652 sertindole Drugs 0.000 description 3
- 239000012312 sodium hydride Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001256 tonic effect Effects 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- 229960002811 ziconotide Drugs 0.000 description 3
- BPKIMPVREBSLAJ-QTBYCLKRSA-N ziconotide Chemical compound C([C@H]1C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]2C(=O)N[C@@H]3C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@H](C(N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CSSC2)C(N)=O)=O)CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC3)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(N1)=O)CCSC)[C@@H](C)O)C1=CC=C(O)C=C1 BPKIMPVREBSLAJ-QTBYCLKRSA-N 0.000 description 3
- 125000006536 (C1-C2)alkoxy group Chemical group 0.000 description 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 2
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 2
- YIWGJFPJRAEKMK-UHFFFAOYSA-N 1-(2H-benzotriazol-5-yl)-3-methyl-8-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carbonyl]-1,3,8-triazaspiro[4.5]decane-2,4-dione Chemical compound CN1C(=O)N(c2ccc3n[nH]nc3c2)C2(CCN(CC2)C(=O)c2cnc(NCc3cccc(OC(F)(F)F)c3)nc2)C1=O YIWGJFPJRAEKMK-UHFFFAOYSA-N 0.000 description 2
- MPPPKRYCTPRNTB-UHFFFAOYSA-N 1-bromobutane Chemical compound CCCCBr MPPPKRYCTPRNTB-UHFFFAOYSA-N 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 description 2
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 2
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 2
- FWRDLKOXFLRXDG-UHFFFAOYSA-N 2-(3-butoxyphenyl)-2-fluoroacetonitrile Chemical compound CCCCOC1=CC=CC(C(F)C#N)=C1 FWRDLKOXFLRXDG-UHFFFAOYSA-N 0.000 description 2
- VJFMTAOCYRLOAL-UHFFFAOYSA-N 2-(3-butoxyphenyl)-2-fluoroethanamine Chemical compound CCCCOC1=CC=CC(C(F)CN)=C1 VJFMTAOCYRLOAL-UHFFFAOYSA-N 0.000 description 2
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 2
- XBPPLECAZBTMMK-UHFFFAOYSA-N 2-chloro-n,n-dimethylacetamide Chemical compound CN(C)C(=O)CCl XBPPLECAZBTMMK-UHFFFAOYSA-N 0.000 description 2
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 2
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 244000215068 Acacia senegal Species 0.000 description 2
- HGINCPLSRVDWNT-UHFFFAOYSA-N Acrolein Chemical compound C=CC=O HGINCPLSRVDWNT-UHFFFAOYSA-N 0.000 description 2
- 206010000599 Acromegaly Diseases 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 description 2
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 206010069918 Bacterial prostatitis Diseases 0.000 description 2
- 206010004142 Bartholinitis Diseases 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- 208000009079 Bronchial Spasm Diseases 0.000 description 2
- 208000014181 Bronchial disease Diseases 0.000 description 2
- 206010006482 Bronchospasm Diseases 0.000 description 2
- DVFRYDFUROFEPY-UHFFFAOYSA-N CCCCOC1=CC=CC(=C1)C(CNCC(=O)N(C)C)F.Cl Chemical compound CCCCOC1=CC=CC(=C1)C(CNCC(=O)N(C)C)F.Cl DVFRYDFUROFEPY-UHFFFAOYSA-N 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 206010064012 Central pain syndrome Diseases 0.000 description 2
- 235000019743 Choline chloride Nutrition 0.000 description 2
- 102000003849 Cytochrome P450 Human genes 0.000 description 2
- 208000016192 Demyelinating disease Diseases 0.000 description 2
- 206010012335 Dependence Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 206010013710 Drug interaction Diseases 0.000 description 2
- 208000001640 Fibromyalgia Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010017753 Gastric atony Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- 201000005569 Gout Diseases 0.000 description 2
- 229920000084 Gum arabic Polymers 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 101100298362 Homo sapiens PPIG gene Proteins 0.000 description 2
- 101000693993 Homo sapiens Sodium channel protein type 4 subunit alpha Proteins 0.000 description 2
- 101000694017 Homo sapiens Sodium channel protein type 5 subunit alpha Proteins 0.000 description 2
- 101000935123 Homo sapiens Voltage-dependent N-type calcium channel subunit alpha-1B Proteins 0.000 description 2
- 208000035154 Hyperesthesia Diseases 0.000 description 2
- 208000005615 Interstitial Cystitis Diseases 0.000 description 2
- 208000032382 Ischaemic stroke Diseases 0.000 description 2
- 108010044467 Isoenzymes Proteins 0.000 description 2
- 102000004016 L-Type Calcium Channels Human genes 0.000 description 2
- 108090000420 L-Type Calcium Channels Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000551546 Minerva Species 0.000 description 2
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 2
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- VCUFZILGIRCDQQ-KRWDZBQOSA-N N-[[(5S)-2-oxo-3-(2-oxo-3H-1,3-benzoxazol-6-yl)-1,3-oxazolidin-5-yl]methyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C1O[C@H](CN1C1=CC2=C(NC(O2)=O)C=C1)CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F VCUFZILGIRCDQQ-KRWDZBQOSA-N 0.000 description 2
- 208000005890 Neuroma Diseases 0.000 description 2
- 102000008299 Nitric Oxide Synthase Human genes 0.000 description 2
- 108010021487 Nitric Oxide Synthase Proteins 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 239000005662 Paraffin oil Substances 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- 208000029082 Pelvic Inflammatory Disease Diseases 0.000 description 2
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 208000005107 Premature Birth Diseases 0.000 description 2
- 206010036590 Premature baby Diseases 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 102100027195 Sodium channel protein type 4 subunit alpha Human genes 0.000 description 2
- 102100027198 Sodium channel protein type 5 subunit alpha Human genes 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 2
- 206010046914 Vaginal infection Diseases 0.000 description 2
- 201000008100 Vaginitis Diseases 0.000 description 2
- 102100025342 Voltage-dependent N-type calcium channel subunit alpha-1B Human genes 0.000 description 2
- JAWMENYCRQKKJY-UHFFFAOYSA-N [3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-ylmethyl)-1-oxa-2,8-diazaspiro[4.5]dec-2-en-8-yl]-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]methanone Chemical compound N1N=NC=2CN(CCC=21)CC1=NOC2(C1)CCN(CC2)C(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F JAWMENYCRQKKJY-UHFFFAOYSA-N 0.000 description 2
- 235000010489 acacia gum Nutrition 0.000 description 2
- 239000000205 acacia gum Substances 0.000 description 2
- 230000036982 action potential Effects 0.000 description 2
- 230000009692 acute damage Effects 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 238000005804 alkylation reaction Methods 0.000 description 2
- 206010053552 allodynia Diseases 0.000 description 2
- 150000003862 amino acid derivatives Chemical class 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000001773 anti-convulsant effect Effects 0.000 description 2
- 229940125681 anticonvulsant agent Drugs 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000000164 antipsychotic agent Substances 0.000 description 2
- 239000002249 anxiolytic agent Substances 0.000 description 2
- 230000000949 anxiolytic effect Effects 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 229940049706 benzodiazepine Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001728 carbonyl compounds Chemical class 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 238000012512 characterization method Methods 0.000 description 2
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 2
- 229960003178 choline chloride Drugs 0.000 description 2
- 230000004087 circulation Effects 0.000 description 2
- OROGSEYTTFOCAN-DNJOTXNNSA-N codeine Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)=C[C@H](O)[C@@H]1OC1=C2C3=CC=C1OC OROGSEYTTFOCAN-DNJOTXNNSA-N 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 230000002920 convulsive effect Effects 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical group OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 229940113088 dimethylacetamide Drugs 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 206010013663 drug dependence Diseases 0.000 description 2
- 238000007876 drug discovery Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 229960002870 gabapentin Drugs 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 229960003878 haloperidol Drugs 0.000 description 2
- 125000005842 heteroatom Chemical group 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 102000056262 human PPIG Human genes 0.000 description 2
- OROGSEYTTFOCAN-UHFFFAOYSA-N hydrocodone Natural products C1C(N(CCC234)C)C2C=CC(O)C3OC2=C4C1=CC=C2OC OROGSEYTTFOCAN-UHFFFAOYSA-N 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000004968 inflammatory condition Effects 0.000 description 2
- 230000000968 intestinal effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 208000017169 kidney disease Diseases 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 239000000787 lecithin Substances 0.000 description 2
- 235000010445 lecithin Nutrition 0.000 description 2
- 229940067606 lecithin Drugs 0.000 description 2
- 238000012417 linear regression Methods 0.000 description 2
- 229960001078 lithium Drugs 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 239000012280 lithium aluminium hydride Substances 0.000 description 2
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 238000011068 loading method Methods 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 208000024714 major depressive disease Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 125000005948 methanesulfonyloxy group Chemical group 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 230000003228 microsomal effect Effects 0.000 description 2
- 210000001589 microsome Anatomy 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 210000003657 middle cerebral artery Anatomy 0.000 description 2
- 229960005181 morphine Drugs 0.000 description 2
- SFMJNHNUOVADRW-UHFFFAOYSA-N n-[5-[9-[4-(methanesulfonamido)phenyl]-2-oxobenzo[h][1,6]naphthyridin-1-yl]-2-methylphenyl]prop-2-enamide Chemical compound C1=C(NC(=O)C=C)C(C)=CC=C1N1C(=O)C=CC2=C1C1=CC(C=3C=CC(NS(C)(=O)=O)=CC=3)=CC=C1N=C2 SFMJNHNUOVADRW-UHFFFAOYSA-N 0.000 description 2
- 229960005016 naphazoline Drugs 0.000 description 2
- 230000000626 neurodegenerative effect Effects 0.000 description 2
- 230000008587 neuronal excitability Effects 0.000 description 2
- 201000001119 neuropathy Diseases 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 230000003957 neurotransmitter release Effects 0.000 description 2
- HYIMSNHJOBLJNT-UHFFFAOYSA-N nifedipine Chemical compound COC(=O)C1=C(C)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1[N+]([O-])=O HYIMSNHJOBLJNT-UHFFFAOYSA-N 0.000 description 2
- 229960001597 nifedipine Drugs 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 description 2
- 208000033808 peripheral neuropathy Diseases 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 229960001233 pregabalin Drugs 0.000 description 2
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 201000007094 prostatitis Diseases 0.000 description 2
- 239000003223 protective agent Substances 0.000 description 2
- 239000003368 psychostimulant agent Substances 0.000 description 2
- LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
- 238000006268 reductive amination reaction Methods 0.000 description 2
- 238000002271 resection Methods 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 238000011808 rodent model Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 230000000698 schizophrenic effect Effects 0.000 description 2
- 210000003497 sciatic nerve Anatomy 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 230000001568 sexual effect Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 229940125794 sodium channel blocker Drugs 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- AEQFSUDEHCCHBT-UHFFFAOYSA-M sodium valproate Chemical compound [Na+].CCCC(C([O-])=O)CCC AEQFSUDEHCCHBT-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000013223 sprague-dawley female rat Methods 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 208000011117 substance-related disease Diseases 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
- FESCNGLPCOVCPO-UHFFFAOYSA-N tert-butyl n-[2-(3-butoxyphenyl)-2,2-difluoroethyl]-n-[1-(dimethylamino)-1-oxopropan-2-yl]carbamate Chemical compound CCCCOC1=CC=CC(C(F)(F)CN(C(C)C(=O)N(C)C)C(=O)OC(C)(C)C)=C1 FESCNGLPCOVCPO-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 2
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 description 2
- 210000000427 trigeminal ganglion Anatomy 0.000 description 2
- 210000003901 trigeminal nerve Anatomy 0.000 description 2
- ZISSAWUMDACLOM-UHFFFAOYSA-N triptane Chemical compound CC(C)C(C)(C)C ZISSAWUMDACLOM-UHFFFAOYSA-N 0.000 description 2
- 238000007492 two-way ANOVA Methods 0.000 description 2
- 208000028394 ureteral disease Diseases 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 229940102566 valproate Drugs 0.000 description 2
- 102000038650 voltage-gated calcium channel activity Human genes 0.000 description 2
- 108091023044 voltage-gated calcium channel activity Proteins 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 229960000833 xylometazoline Drugs 0.000 description 2
- KNJNGVKTAFTUFL-OCMUWRIYSA-N ω-conotoxin Chemical compound N([C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H]1C(N[C@@H](CSSC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H]1C(N[C@@H](CCCN=C(N)N)C(=O)N[C@H](CO)C(=O)NCC(=O)N[C@H](CCCCN)C(=O)N[C@H](CSSC1)C(N)=O)=O)=O)C(=O)[C@@H]1CSSC[C@@H](N)C(=O)N[C@H](CCCCN)C(=O)NCC(=O)N[C@H](CCCCN)C(=O)NCC(=O)N[C@H](C)C(=O)N[C@@H](CCCCN)C(=O)N1 KNJNGVKTAFTUFL-OCMUWRIYSA-N 0.000 description 2
- 108091058550 ω-conotoxin Proteins 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- PMZIUAOBHNJYQT-UHFFFAOYSA-N (1-hydroxy-2-methylpropan-2-yl)azanium;chloride Chemical compound Cl.CC(C)(N)CO PMZIUAOBHNJYQT-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 1
- 229930182837 (R)-adrenaline Natural products 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- MGRVRXRGTBOSHW-UHFFFAOYSA-N (aminomethyl)phosphonic acid Chemical compound NCP(O)(O)=O MGRVRXRGTBOSHW-UHFFFAOYSA-N 0.000 description 1
- IQAAAXGSGUMSBG-WLHGVMLRSA-N (e)-but-2-enedioic acid;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)CC(O)(C(O)=O)CC(O)=O IQAAAXGSGUMSBG-WLHGVMLRSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- 125000004520 1,3,4-thiadiazolyl group Chemical group 0.000 description 1
- ZAUYNCUCMJDAHW-UHFFFAOYSA-N 1-ethenylpyrrolidin-2-one;hydrogen peroxide;molecular iodine Chemical compound OO.II.C=CN1CCCC1=O ZAUYNCUCMJDAHW-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- CFJMRBQWBDQYMK-UHFFFAOYSA-N 1-phenyl-1-cyclopentanecarboxylic acid 2-[2-(diethylamino)ethoxy]ethyl ester Chemical compound C=1C=CC=CC=1C1(C(=O)OCCOCCN(CC)CC)CCCC1 CFJMRBQWBDQYMK-UHFFFAOYSA-N 0.000 description 1
- KCOHFNKWZTUHKD-UHFFFAOYSA-N 2,2-difluoro-2-(3-methoxyphenyl)acetonitrile Chemical compound COC1=CC=CC(C(F)(F)C#N)=C1 KCOHFNKWZTUHKD-UHFFFAOYSA-N 0.000 description 1
- ZFFFRBUYNLKCKK-UHFFFAOYSA-N 2-[[2-(3-butoxyphenyl)-2,2-difluoroethyl]amino]-n,n-dimethylacetamide;hydrochloride Chemical compound Cl.CCCCOC1=CC=CC(C(F)(F)CNCC(=O)N(C)C)=C1 ZFFFRBUYNLKCKK-UHFFFAOYSA-N 0.000 description 1
- WDOAUKIEENWZNC-UHFFFAOYSA-N 2-chloro-n,n-dimethylpropanamide Chemical compound CC(Cl)C(=O)N(C)C WDOAUKIEENWZNC-UHFFFAOYSA-N 0.000 description 1
- VSWICNJIUPRZIK-UHFFFAOYSA-N 2-piperideine Chemical compound C1CNC=CC1 VSWICNJIUPRZIK-UHFFFAOYSA-N 0.000 description 1
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical class C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- 125000003143 4-hydroxybenzyl group Chemical group [H]C([*])([H])C1=C([H])C([H])=C(O[H])C([H])=C1[H] 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 description 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 206010001497 Agitation Diseases 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 102100026882 Alpha-synuclein Human genes 0.000 description 1
- 241000242762 Anemonia sulcata Species 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 208000032467 Aplastic anaemia Diseases 0.000 description 1
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 description 1
- 208000004300 Atrophic Gastritis Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 239000012583 B-27 Supplement Substances 0.000 description 1
- WOVKYSAHUYNSMH-UHFFFAOYSA-N BROMODEOXYURIDINE Natural products C1C(O)C(CO)OC1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-UHFFFAOYSA-N 0.000 description 1
- 208000027496 Behcet disease Diseases 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 206010069632 Bladder dysfunction Diseases 0.000 description 1
- 206010006002 Bone pain Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006550 Bulimia nervosa Diseases 0.000 description 1
- 101150104494 CAV1 gene Proteins 0.000 description 1
- 101150051438 CYP gene Proteins 0.000 description 1
- 101150010738 CYP2D6 gene Proteins 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 101150047856 Cav2 gene Proteins 0.000 description 1
- 101150110214 Cav3 gene Proteins 0.000 description 1
- 206010008025 Cerebellar ataxia Diseases 0.000 description 1
- 206010056874 Chemical cystitis Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- CMKKUZNELLVLIS-UHFFFAOYSA-N Cl.Cl.FC(CNCC(=O)N1CCN(CC1)CC1=CC=CC=C1)(C1=CC(=CC=C1)OCCCC)F Chemical compound Cl.Cl.FC(CNCC(=O)N1CCN(CC1)CC1=CC=CC=C1)(C1=CC(=CC=C1)OCCCC)F CMKKUZNELLVLIS-UHFFFAOYSA-N 0.000 description 1
- HASXBUPMJBAOKH-UHFFFAOYSA-N Cl.FC(CN(CC(=O)N(C)C)C)(C1=CC(=CC=C1)OCCCC)F Chemical compound Cl.FC(CN(CC(=O)N(C)C)C)(C1=CC(=CC=C1)OCCCC)F HASXBUPMJBAOKH-UHFFFAOYSA-N 0.000 description 1
- JTKKGRIXPYVNQN-UHFFFAOYSA-N Cl.FC(CN(CC(=O)N(C)C)CCOC)(C1=CC(=CC=C1)OCCCC)F Chemical compound Cl.FC(CN(CC(=O)N(C)C)CCOC)(C1=CC(=CC=C1)OCCCC)F JTKKGRIXPYVNQN-UHFFFAOYSA-N 0.000 description 1
- ALUJSWWTSLPAHZ-UHFFFAOYSA-N Cl.FC(CNCC(=O)N(C(C)C)C(C)C)(C1=CC(=CC=C1)OCCCC)F Chemical compound Cl.FC(CNCC(=O)N(C(C)C)C(C)C)(C1=CC(=CC=C1)OCCCC)F ALUJSWWTSLPAHZ-UHFFFAOYSA-N 0.000 description 1
- QWTBUELNOJYWMF-UHFFFAOYSA-N Cl.FC(CNCC(=O)N(C)C)(C1=C(C(=CC=C1)OCCCC)F)F Chemical compound Cl.FC(CNCC(=O)N(C)C)(C1=C(C(=CC=C1)OCCCC)F)F QWTBUELNOJYWMF-UHFFFAOYSA-N 0.000 description 1
- HIISBIIZSGDJKE-UHFFFAOYSA-N Cl.FC(CNCC(=O)N(C)C)(C1=CC(=C(C=C1)C)OCCCC)F Chemical compound Cl.FC(CNCC(=O)N(C)C)(C1=CC(=C(C=C1)C)OCCCC)F HIISBIIZSGDJKE-UHFFFAOYSA-N 0.000 description 1
- CWKUKPNCFDEYKE-UHFFFAOYSA-N Cl.FC(CNCC(=O)N(C)C)(C1=CC(=CC=C1)OCC1=C(C=CC=C1)F)F Chemical compound Cl.FC(CNCC(=O)N(C)C)(C1=CC(=CC=C1)OCC1=C(C=CC=C1)F)F CWKUKPNCFDEYKE-UHFFFAOYSA-N 0.000 description 1
- BIJCRFSFLMLDAV-UHFFFAOYSA-N Cl.FC(CNCC(=O)N(C)C)(C1=CC(=CC=C1)OCC1=CC=CC=C1)F Chemical compound Cl.FC(CNCC(=O)N(C)C)(C1=CC(=CC=C1)OCC1=CC=CC=C1)F BIJCRFSFLMLDAV-UHFFFAOYSA-N 0.000 description 1
- JHCGZHXQOFFWGR-UHFFFAOYSA-N Cl.FC(CNCC(=O)N(C)C)(C1=CC(=CC=C1)OCCCC(F)(F)F)F Chemical compound Cl.FC(CNCC(=O)N(C)C)(C1=CC(=CC=C1)OCCCC(F)(F)F)F JHCGZHXQOFFWGR-UHFFFAOYSA-N 0.000 description 1
- LHNQFKBSGCQXJH-UHFFFAOYSA-N Cl.FC(CNCC(=O)N(C)C)(C1=CC(=CC=C1)OCCCC1=CC=CC=C1)F Chemical compound Cl.FC(CNCC(=O)N(C)C)(C1=CC(=CC=C1)OCCCC1=CC=CC=C1)F LHNQFKBSGCQXJH-UHFFFAOYSA-N 0.000 description 1
- RXJDEBJPZZFFHT-UHFFFAOYSA-N Cl.FC(CNCC(=O)N(C)C)(C1=CC(=CC=C1)OCCCC=1SC=CN1)F Chemical compound Cl.FC(CNCC(=O)N(C)C)(C1=CC(=CC=C1)OCCCC=1SC=CN1)F RXJDEBJPZZFFHT-UHFFFAOYSA-N 0.000 description 1
- UYCIVWCTUMYRPT-UHFFFAOYSA-N Cl.FC(CNCC(=O)N(C)C)(C1=CC(=CC=C1)OCCCCC)F Chemical compound Cl.FC(CNCC(=O)N(C)C)(C1=CC(=CC=C1)OCCCCC)F UYCIVWCTUMYRPT-UHFFFAOYSA-N 0.000 description 1
- VMNXVMXETIIWDB-UHFFFAOYSA-N Cl.FC(CNCC(=O)N(C)C)(C1=CC(=CC=C1)OCCCCCC)F Chemical compound Cl.FC(CNCC(=O)N(C)C)(C1=CC(=CC=C1)OCCCCCC)F VMNXVMXETIIWDB-UHFFFAOYSA-N 0.000 description 1
- NBTMGEHFVVLUAL-UHFFFAOYSA-N Cl.FC(CNCC(=O)N(C)C)C1=CC(=CC=C1)OCC1=CC(=CC=C1)Cl Chemical compound Cl.FC(CNCC(=O)N(C)C)C1=CC(=CC=C1)OCC1=CC(=CC=C1)Cl NBTMGEHFVVLUAL-UHFFFAOYSA-N 0.000 description 1
- PLPGZTOKCXMGNP-UHFFFAOYSA-N Cl.FC(CNCC(=O)N(C)C)C1=CC(=CC=C1)OCC1=CC(=CC=C1)F Chemical compound Cl.FC(CNCC(=O)N(C)C)C1=CC(=CC=C1)OCC1=CC(=CC=C1)F PLPGZTOKCXMGNP-UHFFFAOYSA-N 0.000 description 1
- GAUOYOIBRYJJMZ-UHFFFAOYSA-N Cl.FC(CNCC(=O)N(C)C1CCCCC1)(C1=CC(=CC=C1)OCCCC)F Chemical compound Cl.FC(CNCC(=O)N(C)C1CCCCC1)(C1=CC(=CC=C1)OCCCC)F GAUOYOIBRYJJMZ-UHFFFAOYSA-N 0.000 description 1
- ADYMUYIXLUPWIJ-UHFFFAOYSA-N Cl.FC(CNCC(=O)N(C1=CC=CC=C1)C)(C1=CC(=CC=C1)OCCCC(F)(F)F)F Chemical compound Cl.FC(CNCC(=O)N(C1=CC=CC=C1)C)(C1=CC(=CC=C1)OCCCC(F)(F)F)F ADYMUYIXLUPWIJ-UHFFFAOYSA-N 0.000 description 1
- LFJVUFZLHKKPPI-UHFFFAOYSA-N Cl.FC(CNCC(=O)N(C1=CC=CC=C1)C)(C1=CC(=CC=C1)OCCCC)F Chemical compound Cl.FC(CNCC(=O)N(C1=CC=CC=C1)C)(C1=CC(=CC=C1)OCCCC)F LFJVUFZLHKKPPI-UHFFFAOYSA-N 0.000 description 1
- IAUFIFSNULZMEP-UHFFFAOYSA-N Cl.FC(CNCC(=O)N(C1=CC=CC=C1)C)(C1=CC(=CC=C1)OCCCC1=CC=CC=C1)F Chemical compound Cl.FC(CNCC(=O)N(C1=CC=CC=C1)C)(C1=CC(=CC=C1)OCCCC1=CC=CC=C1)F IAUFIFSNULZMEP-UHFFFAOYSA-N 0.000 description 1
- BSYGYHBXGLYRDI-UHFFFAOYSA-N Cl.FC(CNCC(=O)N(CC)CC)(C1=CC(=CC=C1)OCCCC)F Chemical compound Cl.FC(CNCC(=O)N(CC)CC)(C1=CC(=CC=C1)OCCCC)F BSYGYHBXGLYRDI-UHFFFAOYSA-N 0.000 description 1
- FNFGKOCYLGVFHA-UHFFFAOYSA-N Cl.FC(CNCC(=O)N(CCC)CCC)(C1=CC(=CC=C1)OCCCC)F Chemical compound Cl.FC(CNCC(=O)N(CCC)CCC)(C1=CC(=CC=C1)OCCCC)F FNFGKOCYLGVFHA-UHFFFAOYSA-N 0.000 description 1
- VHVCJSWVDSXVAH-UHFFFAOYSA-N Cl.FC(CNCC(=O)N(CCC)CCC)(C1=CC(=CC=C1)OCCCCC)F Chemical compound Cl.FC(CNCC(=O)N(CCC)CCC)(C1=CC(=CC=C1)OCCCCC)F VHVCJSWVDSXVAH-UHFFFAOYSA-N 0.000 description 1
- STFVDYQYIOJSSE-UHFFFAOYSA-N Cl.FC(CNCC(=O)N(CCCC)CCCC)(C1=CC(=CC=C1)OCCCC)F Chemical compound Cl.FC(CNCC(=O)N(CCCC)CCCC)(C1=CC(=CC=C1)OCCCC)F STFVDYQYIOJSSE-UHFFFAOYSA-N 0.000 description 1
- OFBNGEJIGSPKNL-UHFFFAOYSA-N Cl.FC(CNCC(=O)N1CC2=CC=CC=C2CC1)(C1=CC(=CC=C1)OCCCC)F Chemical compound Cl.FC(CNCC(=O)N1CC2=CC=CC=C2CC1)(C1=CC(=CC=C1)OCCCC)F OFBNGEJIGSPKNL-UHFFFAOYSA-N 0.000 description 1
- DKJQKPHBJONQEK-UHFFFAOYSA-N Cl.FC(CNCC(=O)N1CCC2=CC=CC=C12)(C1=CC(=CC=C1)OCCCC)F Chemical compound Cl.FC(CNCC(=O)N1CCC2=CC=CC=C12)(C1=CC(=CC=C1)OCCCC)F DKJQKPHBJONQEK-UHFFFAOYSA-N 0.000 description 1
- OSDXFLPNPIBDPG-UHFFFAOYSA-N Cl.FC(CNCC(=O)N1CCCC1)(C1=CC(=CC=C1)OCC1=CC=CC=C1)F Chemical compound Cl.FC(CNCC(=O)N1CCCC1)(C1=CC(=CC=C1)OCC1=CC=CC=C1)F OSDXFLPNPIBDPG-UHFFFAOYSA-N 0.000 description 1
- IPOKLTQVAUXFQV-UHFFFAOYSA-N Cl.FC(CNCC(=O)N1CCCC1)(C1=CC(=CC=C1)OCCCC)F Chemical compound Cl.FC(CNCC(=O)N1CCCC1)(C1=CC(=CC=C1)OCCCC)F IPOKLTQVAUXFQV-UHFFFAOYSA-N 0.000 description 1
- PHEJTPQEUSCYRE-UHFFFAOYSA-N Cl.FC(CNCC(=O)N1CCCC1)(C1=CC(=CC=C1)OCCCC1=CC=CC=C1)F Chemical compound Cl.FC(CNCC(=O)N1CCCC1)(C1=CC(=CC=C1)OCCCC1=CC=CC=C1)F PHEJTPQEUSCYRE-UHFFFAOYSA-N 0.000 description 1
- IHCCKMAPAXSUNY-UHFFFAOYSA-N Cl.FC(CNCC(=O)N1CCCCC1)(C1=CC(=CC=C1)OCC1=CC=CC=C1)F Chemical compound Cl.FC(CNCC(=O)N1CCCCC1)(C1=CC(=CC=C1)OCC1=CC=CC=C1)F IHCCKMAPAXSUNY-UHFFFAOYSA-N 0.000 description 1
- RVCTUIZMMNRZKD-UHFFFAOYSA-N Cl.FC(CNCC(=O)N1CCCCC1)(C1=CC(=CC=C1)OCCCC(F)(F)F)F Chemical compound Cl.FC(CNCC(=O)N1CCCCC1)(C1=CC(=CC=C1)OCCCC(F)(F)F)F RVCTUIZMMNRZKD-UHFFFAOYSA-N 0.000 description 1
- BHILXODSPHVTJU-UHFFFAOYSA-N Cl.FC(CNCC(=O)N1CCCCC1)(C1=CC(=CC=C1)OCCCC)F Chemical compound Cl.FC(CNCC(=O)N1CCCCC1)(C1=CC(=CC=C1)OCCCC)F BHILXODSPHVTJU-UHFFFAOYSA-N 0.000 description 1
- VRGRTKKMPWHOQB-UHFFFAOYSA-N Cl.FC(CNCC(=O)N1CCCCC1)(C1=CC(=CC=C1)OCCCC1=CC=CC=C1)F Chemical compound Cl.FC(CNCC(=O)N1CCCCC1)(C1=CC(=CC=C1)OCCCC1=CC=CC=C1)F VRGRTKKMPWHOQB-UHFFFAOYSA-N 0.000 description 1
- RLAXWGDVSVEXCL-UHFFFAOYSA-N Cl.FC(CNCC(=O)N1CCN(CC1)C)(C1=CC(=CC=C1)OCCCC(F)(F)F)F Chemical compound Cl.FC(CNCC(=O)N1CCN(CC1)C)(C1=CC(=CC=C1)OCCCC(F)(F)F)F RLAXWGDVSVEXCL-UHFFFAOYSA-N 0.000 description 1
- GVZWBWDZKSNDLO-UHFFFAOYSA-N Cl.FC(CNCC(=O)N1CCN(CC1)C)(C1=CC(=CC=C1)OCCCC)F Chemical compound Cl.FC(CNCC(=O)N1CCN(CC1)C)(C1=CC(=CC=C1)OCCCC)F GVZWBWDZKSNDLO-UHFFFAOYSA-N 0.000 description 1
- CRDPVGIVAUXUHA-UHFFFAOYSA-N Cl.FC(CNCC(=O)N1CCN(CC1)C)(C1=CC(=CC=C1)OCCCC1=CC=CC=C1)F Chemical compound Cl.FC(CNCC(=O)N1CCN(CC1)C)(C1=CC(=CC=C1)OCCCC1=CC=CC=C1)F CRDPVGIVAUXUHA-UHFFFAOYSA-N 0.000 description 1
- LXIHRBFCSCWXRX-UHFFFAOYSA-N Cl.FC(CNCC(=O)N1CCN(CC1)S(=O)(=O)C1=CC=CC=C1)(C1=CC(=CC=C1)OCCCC)F Chemical compound Cl.FC(CNCC(=O)N1CCN(CC1)S(=O)(=O)C1=CC=CC=C1)(C1=CC(=CC=C1)OCCCC)F LXIHRBFCSCWXRX-UHFFFAOYSA-N 0.000 description 1
- GYVHAGSZAQUEAD-UHFFFAOYSA-N Cl.FC(CNCC(=O)N1CCOCC1)(C1=CC(=CC=C1)OCC1=CC=CC=C1)F Chemical compound Cl.FC(CNCC(=O)N1CCOCC1)(C1=CC(=CC=C1)OCC1=CC=CC=C1)F GYVHAGSZAQUEAD-UHFFFAOYSA-N 0.000 description 1
- ADFQKQFOKHEPKL-UHFFFAOYSA-N Cl.FC(CNCC(=O)N1CCOCC1)(C1=CC(=CC=C1)OCCCC(F)(F)F)F Chemical compound Cl.FC(CNCC(=O)N1CCOCC1)(C1=CC(=CC=C1)OCCCC(F)(F)F)F ADFQKQFOKHEPKL-UHFFFAOYSA-N 0.000 description 1
- KBMBTAWGYTZZHL-UHFFFAOYSA-N Cl.FC(CNCC(=O)N1CCOCC1)(C1=CC(=CC=C1)OCCCC1=CC=CC=C1)F Chemical compound Cl.FC(CNCC(=O)N1CCOCC1)(C1=CC(=CC=C1)OCCCC1=CC=CC=C1)F KBMBTAWGYTZZHL-UHFFFAOYSA-N 0.000 description 1
- WEXWRVHGZZGABU-OKZTUQRJSA-N Cl.FC(CNCC(=O)N1C[C@H](C[C@H](C1)C)C)(C1=CC(=CC=C1)OCCCC)F Chemical compound Cl.FC(CNCC(=O)N1C[C@H](C[C@H](C1)C)C)(C1=CC(=CC=C1)OCCCC)F WEXWRVHGZZGABU-OKZTUQRJSA-N 0.000 description 1
- 206010053398 Clonic convulsion Diseases 0.000 description 1
- 208000006561 Cluster Headache Diseases 0.000 description 1
- 208000015943 Coeliac disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000033001 Complex partial seizures Diseases 0.000 description 1
- 208000013586 Complex regional pain syndrome type 1 Diseases 0.000 description 1
- 208000006509 Congenital Pain Insensitivity Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 108010037464 Cyclooxygenase 1 Proteins 0.000 description 1
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 1
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 1
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- KDXKERNSBIXSRK-RXMQYKEDSA-N D-lysine Chemical compound NCCCC[C@@H](N)C(O)=O KDXKERNSBIXSRK-RXMQYKEDSA-N 0.000 description 1
- 208000024254 Delusional disease Diseases 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 208000005872 Diffuse Esophageal Spasm Diseases 0.000 description 1
- 238000001061 Dunnett's test Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000027534 Emotional disease Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 208000024720 Fabry Disease Diseases 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 201000011240 Frontotemporal dementia Diseases 0.000 description 1
- 208000037767 Gallbladder pain Diseases 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 208000036495 Gastritis atrophic Diseases 0.000 description 1
- 208000017228 Gastrointestinal motility disease Diseases 0.000 description 1
- 241000237858 Gastropoda Species 0.000 description 1
- 208000011688 Generalised anxiety disease Diseases 0.000 description 1
- 206010071602 Genetic polymorphism Diseases 0.000 description 1
- 229940127337 Glycine Antagonists Drugs 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 description 1
- 101000896586 Homo sapiens Cytochrome P450 2D6 Proteins 0.000 description 1
- 101000684826 Homo sapiens Sodium channel protein type 2 subunit alpha Proteins 0.000 description 1
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 1
- 101000932790 Homo sapiens Voltage-dependent L-type calcium channel subunit alpha-1S Proteins 0.000 description 1
- 101000867850 Homo sapiens Voltage-dependent T-type calcium channel subunit alpha-1G Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021030 Hypomania Diseases 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- MKXZASYAUGDDCJ-SZMVWBNQSA-N LSM-2525 Chemical compound C1CCC[C@H]2[C@@]3([H])N(C)CC[C@]21C1=CC(OC)=CC=C1C3 MKXZASYAUGDDCJ-SZMVWBNQSA-N 0.000 description 1
- 208000007914 Labor Pain Diseases 0.000 description 1
- 208000035945 Labour pain Diseases 0.000 description 1
- 208000009829 Lewy Body Disease Diseases 0.000 description 1
- 201000002832 Lewy body dementia Diseases 0.000 description 1
- 229910010082 LiAlH Inorganic materials 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 239000000867 Lipoxygenase Inhibitor Substances 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 206010024715 Liver transplant rejection Diseases 0.000 description 1
- 206010048961 Localised oedema Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000037039 Monarthritis Diseases 0.000 description 1
- 208000002472 Morton Neuroma Diseases 0.000 description 1
- 208000020059 Morton neuralgia Diseases 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010065673 Nephritic syndrome Diseases 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 206010029315 Neuromuscular blockade Diseases 0.000 description 1
- 102000019315 Nicotinic acetylcholine receptors Human genes 0.000 description 1
- 108050006807 Nicotinic acetylcholine receptors Proteins 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 102100022397 Nitric oxide synthase, brain Human genes 0.000 description 1
- 101710111444 Nitric oxide synthase, brain Proteins 0.000 description 1
- 102100029438 Nitric oxide synthase, inducible Human genes 0.000 description 1
- 101710089543 Nitric oxide synthase, inducible Proteins 0.000 description 1
- 206010062501 Non-cardiac chest pain Diseases 0.000 description 1
- 206010029897 Obsessive thoughts Diseases 0.000 description 1
- 206010030184 Oesophageal spasm Diseases 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- 208000037158 Partial Epilepsies Diseases 0.000 description 1
- 208000000450 Pelvic Pain Diseases 0.000 description 1
- 206010034464 Periarthritis Diseases 0.000 description 1
- 208000010886 Peripheral nerve injury Diseases 0.000 description 1
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 description 1
- 208000004983 Phantom Limb Diseases 0.000 description 1
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
- 206010034912 Phobia Diseases 0.000 description 1
- 240000007643 Phytolacca americana Species 0.000 description 1
- 229920001214 Polysorbate 60 Polymers 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 206010036376 Postherpetic Neuralgia Diseases 0.000 description 1
- 208000004550 Postoperative Pain Diseases 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 206010036774 Proctitis Diseases 0.000 description 1
- 102100038277 Prostaglandin G/H synthase 1 Human genes 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108091008109 Pseudogenes Proteins 0.000 description 1
- 102000057361 Pseudogenes Human genes 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 description 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 description 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010037779 Radiculopathy Diseases 0.000 description 1
- 201000001947 Reflex Sympathetic Dystrophy Diseases 0.000 description 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 1
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 1
- 208000008765 Sciatica Diseases 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 101150080511 Scn9a gene Proteins 0.000 description 1
- 208000017143 Secondary Headache disease Diseases 0.000 description 1
- 208000019568 Shared Paranoid disease Diseases 0.000 description 1
- 208000028810 Shared psychotic disease Diseases 0.000 description 1
- 206010040703 Simple partial seizures Diseases 0.000 description 1
- 101710134422 Sodium channel protein type 10 subunit alpha Proteins 0.000 description 1
- 102100023150 Sodium channel protein type 2 subunit alpha Human genes 0.000 description 1
- 208000027520 Somatoform disease Diseases 0.000 description 1
- 208000029033 Spinal Cord disease Diseases 0.000 description 1
- 208000010112 Spinocerebellar Degenerations Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- 208000034799 Tauopathies Diseases 0.000 description 1
- 208000008548 Tension-Type Headache Diseases 0.000 description 1
- KLBQZWRITKRQQV-UHFFFAOYSA-N Thioridazine Chemical compound C12=CC(SC)=CC=C2SC2=CC=CC=C2N1CCC1CCCCN1C KLBQZWRITKRQQV-UHFFFAOYSA-N 0.000 description 1
- 206010043994 Tonic convulsion Diseases 0.000 description 1
- 208000010641 Tooth disease Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 description 1
- FVECELJHCSPHKY-UHFFFAOYSA-N Veratridine Natural products C1=C(OC)C(OC)=CC=C1C(=O)OC1C2(O)OC34CC5(O)C(CN6C(CCC(C)C6)C6(C)O)C6(O)C(O)CC5(O)C4CCC2C3(C)CC1 FVECELJHCSPHKY-UHFFFAOYSA-N 0.000 description 1
- 102100025485 Voltage-dependent L-type calcium channel subunit alpha-1S Human genes 0.000 description 1
- 102100025330 Voltage-dependent P/Q-type calcium channel subunit alpha-1A Human genes 0.000 description 1
- 102100033024 Voltage-dependent T-type calcium channel subunit alpha-1G Human genes 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 208000028311 absence seizure Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002582 adenosine A1 receptor agonist Substances 0.000 description 1
- 239000003449 adenosine A2 receptor antagonist Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 210000003152 adnexa uteri Anatomy 0.000 description 1
- 239000000048 adrenergic agonist Substances 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 201000007930 alcohol dependence Diseases 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 125000001118 alkylidene group Chemical group 0.000 description 1
- 108090000185 alpha-Synuclein Proteins 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 230000006933 amyloid-beta aggregation Effects 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 230000003872 anastomosis Effects 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 229940069428 antacid Drugs 0.000 description 1
- 239000003159 antacid agent Substances 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 230000003474 anti-emetic effect Effects 0.000 description 1
- 230000002460 anti-migrenic effect Effects 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 229940127226 anticholesterol agent Drugs 0.000 description 1
- 229940125683 antiemetic agent Drugs 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 229940082992 antihypertensives mao inhibitors Drugs 0.000 description 1
- 229940005529 antipsychotics Drugs 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 229940124584 antitussives Drugs 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940005530 anxiolytics Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960004372 aripiprazole Drugs 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000002917 arthritic effect Effects 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000000440 benzylamino group Chemical group [H]N(*)C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 239000005388 borosilicate glass Substances 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 229950004398 broxuridine Drugs 0.000 description 1
- CJGYSWNGNKCJSB-YVLZZHOMSA-N bucladesine Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](OC(=O)CCC)[C@@H]2N1C(N=CN=C2NC(=O)CCC)=C2N=C1 CJGYSWNGNKCJSB-YVLZZHOMSA-N 0.000 description 1
- 229960005263 bucladesine Drugs 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229960001948 caffeine Drugs 0.000 description 1
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
- 230000009460 calcium influx Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229930003827 cannabinoid Natural products 0.000 description 1
- 239000003557 cannabinoid Substances 0.000 description 1
- 229940065144 cannabinoids Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000003543 catechol methyltransferase inhibitor Substances 0.000 description 1
- 150000003943 catecholamines Chemical class 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 231100000481 chemical toxicant Toxicity 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 239000000544 cholinesterase inhibitor Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 1
- 208000019069 chronic childhood arthritis Diseases 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 1
- LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 230000002060 circadian Effects 0.000 description 1
- 229960004170 clozapine Drugs 0.000 description 1
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 1
- 208000018912 cluster headache syndrome Diseases 0.000 description 1
- 238000011260 co-administration Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229960004126 codeine Drugs 0.000 description 1
- 208000008609 collagenous colitis Diseases 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 230000002301 combined effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- FNIATMYXUPOJRW-UHFFFAOYSA-N cyclohexylidene Chemical group [C]1CCCCC1 FNIATMYXUPOJRW-UHFFFAOYSA-N 0.000 description 1
- 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 239000000850 decongestant Substances 0.000 description 1
- 229940124581 decongestants Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 239000003479 dental cement Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960001985 dextromethorphan Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 201000010064 diabetes insipidus Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- XYYVYLMBEZUESM-UHFFFAOYSA-N dihydrocodeine Natural products C1C(N(CCC234)C)C2C=CC(=O)C3OC2=C4C1=CC=C2OC XYYVYLMBEZUESM-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- AMTWCFIAVKBGOD-UHFFFAOYSA-N dioxosilane;methoxy-dimethyl-trimethylsilyloxysilane Chemical compound O=[Si]=O.CO[Si](C)(C)O[Si](C)(C)C AMTWCFIAVKBGOD-UHFFFAOYSA-N 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- DLNKOYKMWOXYQA-UHFFFAOYSA-N dl-pseudophenylpropanolamine Natural products CC(N)C(O)C1=CC=CC=C1 DLNKOYKMWOXYQA-UHFFFAOYSA-N 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 229940052760 dopamine agonists Drugs 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000036267 drug metabolism Effects 0.000 description 1
- 238000003255 drug test Methods 0.000 description 1
- 230000008406 drug-drug interaction Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 210000001951 dura mater Anatomy 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000003821 enantio-separation Methods 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 201000003104 endogenous depression Diseases 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 208000037902 enteropathy Diseases 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 description 1
- 229960005139 epinephrine Drugs 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 201000011384 erythromelalgia Diseases 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 201000006517 essential tremor Diseases 0.000 description 1
- WHQLQYRFIHPMNA-UHFFFAOYSA-N ethyl acetate;oxolane Chemical compound C1CCOC1.CCOC(C)=O WHQLQYRFIHPMNA-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 230000002964 excitative effect Effects 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 210000001105 femoral artery Anatomy 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 239000007941 film coated tablet Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- SMANXXCATUTDDT-QPJJXVBHSA-N flunarizine Chemical compound C1=CC(F)=CC=C1C(C=1C=CC(F)=CC=1)N1CCN(C\C=C\C=2C=CC=CC=2)CC1 SMANXXCATUTDDT-QPJJXVBHSA-N 0.000 description 1
- 229960000326 flunarizine Drugs 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 239000012025 fluorinating agent Substances 0.000 description 1
- 238000003682 fluorination reaction Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 230000009454 functional inhibition Effects 0.000 description 1
- 230000005021 gait Effects 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 230000005176 gastrointestinal motility Effects 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 208000029364 generalized anxiety disease Diseases 0.000 description 1
- 208000007565 gingivitis Diseases 0.000 description 1
- 102000010705 glucose-6-phosphate dehydrogenase activity proteins Human genes 0.000 description 1
- 108040005050 glucose-6-phosphate dehydrogenase activity proteins Proteins 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 208000024798 heartburn Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000010224 hepatic metabolism Effects 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 208000010710 hepatitis C virus infection Diseases 0.000 description 1
- 208000037584 hereditary sensory and autonomic neuropathy Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000000938 histamine H1 antagonist Substances 0.000 description 1
- 210000004754 hybrid cell Anatomy 0.000 description 1
- LLPOLZWFYMWNKH-CMKMFDCUSA-N hydrocodone Chemical compound C([C@H]1[C@H](N(CC[C@@]112)C)C3)CC(=O)[C@@H]1OC1=C2C3=CC=C1OC LLPOLZWFYMWNKH-CMKMFDCUSA-N 0.000 description 1
- 229960000240 hydrocodone Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 230000002806 hypometabolic effect Effects 0.000 description 1
- 208000009326 ileitis Diseases 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000002055 immunohistochemical effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 239000003978 infusion fluid Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 208000028774 intestinal disease Diseases 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000036724 intravesical pressure Effects 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 230000003447 ipsilateral effect Effects 0.000 description 1
- 208000002551 irritable bowel syndrome Diseases 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 208000018937 joint inflammation Diseases 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 244000145841 kine Species 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 229940065725 leukotriene receptor antagonists for obstructive airway diseases Drugs 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229960004393 lidocaine hydrochloride Drugs 0.000 description 1
- YECIFGHRMFEPJK-UHFFFAOYSA-N lidocaine hydrochloride monohydrate Chemical compound O.[Cl-].CC[NH+](CC)CC(=O)NC1=C(C)C=CC=C1C YECIFGHRMFEPJK-UHFFFAOYSA-N 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 230000003137 locomotive effect Effects 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940023568 magnesium valproate Drugs 0.000 description 1
- LKLLHOIUJVEAGU-UHFFFAOYSA-L magnesium;2-propylpentanoate Chemical compound [Mg+2].CCCC(C([O-])=O)CCC.CCCC(C([O-])=O)CCC LKLLHOIUJVEAGU-UHFFFAOYSA-L 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000003475 metalloproteinase inhibitor Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 208000008275 microscopic colitis Diseases 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 1
- 230000001730 monoaminergic effect Effects 0.000 description 1
- 201000005518 mononeuropathy Diseases 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000037023 motor activity Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000002464 muscle smooth vascular Anatomy 0.000 description 1
- 206010028417 myasthenia gravis Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- AJFDBNQQDYLMJN-UHFFFAOYSA-N n,n-diethylacetamide Chemical compound CCN(CC)C(C)=O AJFDBNQQDYLMJN-UHFFFAOYSA-N 0.000 description 1
- AJWNYPNPXLNRAO-UHFFFAOYSA-N n-(1,3-thiazol-2-yl)benzenesulfonamide Chemical compound C=1C=CC=CC=1S(=O)(=O)NC1=NC=CS1 AJWNYPNPXLNRAO-UHFFFAOYSA-N 0.000 description 1
- UNHGSHHVDNGCFN-UHFFFAOYSA-N naratriptan Chemical compound C=12[CH]C(CCS(=O)(=O)NC)=CC=C2N=CC=1C1CCN(C)CC1 UNHGSHHVDNGCFN-UHFFFAOYSA-N 0.000 description 1
- 229960005254 naratriptan Drugs 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 229940105631 nembutal Drugs 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000004770 neurodegeneration Effects 0.000 description 1
- 239000000842 neuromuscular blocking agent Substances 0.000 description 1
- 230000016273 neuron death Effects 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 210000000929 nociceptor Anatomy 0.000 description 1
- 108091008700 nociceptors Proteins 0.000 description 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 1
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- SBQLYHNEIUGQKH-UHFFFAOYSA-N omeprazole Chemical compound N1=C2[CH]C(OC)=CC=C2N=C1S(=O)CC1=NC=C(C)C(OC)=C1C SBQLYHNEIUGQKH-UHFFFAOYSA-N 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 239000000014 opioid analgesic Substances 0.000 description 1
- 229940005483 opioid analgesics Drugs 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229960001528 oxymetazoline Drugs 0.000 description 1
- 208000027753 pain disease Diseases 0.000 description 1
- 230000008052 pain pathway Effects 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 238000007427 paired t-test Methods 0.000 description 1
- GVEAYVLWDAFXET-XGHATYIMSA-N pancuronium Chemical compound C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 GVEAYVLWDAFXET-XGHATYIMSA-N 0.000 description 1
- 229960005457 pancuronium Drugs 0.000 description 1
- 229960003379 pancuronium bromide Drugs 0.000 description 1
- NPIJXCQZLFKBMV-YTGGZNJNSA-L pancuronium bromide Chemical compound [Br-].[Br-].C[N+]1([C@@H]2[C@@H](OC(C)=O)C[C@@H]3CC[C@H]4[C@@H]5C[C@@H]([C@@H]([C@]5(CC[C@@H]4[C@@]3(C)C2)C)OC(=O)C)[N+]2(C)CCCCC2)CCCCC1 NPIJXCQZLFKBMV-YTGGZNJNSA-L 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 208000002851 paranoid schizophrenia Diseases 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 230000001314 paroxysmal effect Effects 0.000 description 1
- 230000007310 pathophysiology Effects 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229960003436 pentoxyverine Drugs 0.000 description 1
- 230000010412 perfusion Effects 0.000 description 1
- 210000002856 peripheral neuron Anatomy 0.000 description 1
- 210000005223 peripheral sensory neuron Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 229960000762 perphenazine Drugs 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 208000022821 personality disease Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003395 phenylethylamino group Chemical group [H]N(*)C([H])([H])C([H])([H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229960000395 phenylpropanolamine Drugs 0.000 description 1
- DLNKOYKMWOXYQA-APPZFPTMSA-N phenylpropanolamine Chemical compound C[C@@H](N)[C@H](O)C1=CC=CC=C1 DLNKOYKMWOXYQA-APPZFPTMSA-N 0.000 description 1
- 229960002036 phenytoin Drugs 0.000 description 1
- 208000019899 phobic disease Diseases 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- IVXQBCUBSIPQGU-UHFFFAOYSA-N piperazine-1-carboxamide Chemical class NC(=O)N1CCNCC1 IVXQBCUBSIPQGU-UHFFFAOYSA-N 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 208000028173 post-traumatic stress disease Diseases 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960000786 propylhexedrine Drugs 0.000 description 1
- JCRIVQIOJSSCQD-UHFFFAOYSA-N propylhexedrine Chemical compound CNC(C)CC1CCCCC1 JCRIVQIOJSSCQD-UHFFFAOYSA-N 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229940126409 proton pump inhibitor Drugs 0.000 description 1
- 239000000612 proton pump inhibitor Substances 0.000 description 1
- 229960003908 pseudoephedrine Drugs 0.000 description 1
- KWGRBVOPPLSCSI-WCBMZHEXSA-N pseudoephedrine Chemical compound CN[C@@H](C)[C@@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WCBMZHEXSA-N 0.000 description 1
- 230000001696 purinergic effect Effects 0.000 description 1
- 210000000449 purkinje cell Anatomy 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- SZVWBINNBHRDJG-UHFFFAOYSA-N pyridin-2-amine;sodium Chemical compound [Na].NC1=CC=CC=N1 SZVWBINNBHRDJG-UHFFFAOYSA-N 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 150000003246 quinazolines Chemical class 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 229960001404 quinidine Drugs 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000006833 reintegration Effects 0.000 description 1
- 230000036390 resting membrane potential Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000009183 running Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003335 secondary amines Chemical class 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 230000001624 sedative effect Effects 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- 239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 1
- 230000001953 sensory effect Effects 0.000 description 1
- 230000020341 sensory perception of pain Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229940083037 simethicone Drugs 0.000 description 1
- 210000003625 skull Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000001032 spinal nerve Anatomy 0.000 description 1
- 210000005250 spinal neuron Anatomy 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000003890 substance P antagonist Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- KQKPFRSPSRPDEB-UHFFFAOYSA-N sumatriptan Chemical compound CNS(=O)(=O)CC1=CC=C2NC=C(CCN(C)C)C2=C1 KQKPFRSPSRPDEB-UHFFFAOYSA-N 0.000 description 1
- 229960003708 sumatriptan Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
- 230000035488 systolic blood pressure Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- HGLHEJGZVCXIRI-UHFFFAOYSA-N tert-butyl n-[2-(3-butoxyphenyl)-2,2-difluoroethyl]-n-[2-(dimethylamino)-2-oxoethyl]carbamate Chemical compound CCCCOC1=CC=CC(C(F)(F)CN(CC(=O)N(C)C)C(=O)OC(C)(C)C)=C1 HGLHEJGZVCXIRI-UHFFFAOYSA-N 0.000 description 1
- CUPFLKKXKITNSM-UHFFFAOYSA-N tert-butyl n-[2-(3-butoxyphenyl)-2,2-difluoroethyl]carbamate Chemical compound CCCCOC1=CC=CC(C(F)(F)CNC(=O)OC(C)(C)C)=C1 CUPFLKKXKITNSM-UHFFFAOYSA-N 0.000 description 1
- IXNWSUBDWCQFEL-UHFFFAOYSA-N tert-butyl n-[2-(3-butoxyphenyl)-2-fluoroethyl]carbamate Chemical compound CCCCOC1=CC=CC(C(F)CNC(=O)OC(C)(C)C)=C1 IXNWSUBDWCQFEL-UHFFFAOYSA-N 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- IWXDXDCALKLIKB-UHFFFAOYSA-N tert-butylperoxycarbonyl (2-methylpropan-2-yl)oxy carbonate Chemical compound CC(C)(C)OOC(=O)OC(=O)OOC(C)(C)C IWXDXDCALKLIKB-UHFFFAOYSA-N 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000006223 tetrahydrofuranylmethyl group Chemical group 0.000 description 1
- 208000012720 thalamic disease Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960002784 thioridazine Drugs 0.000 description 1
- 206010048627 thoracic outlet syndrome Diseases 0.000 description 1
- 206010043778 thyroiditis Diseases 0.000 description 1
- 208000004371 toothache Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- LLPOLZWFYMWNKH-UHFFFAOYSA-N trans-dihydrocodeinone Natural products C1C(N(CCC234)C)C2CCC(=O)C3OC2=C4C1=CC=C2OC LLPOLZWFYMWNKH-UHFFFAOYSA-N 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000006493 trifluoromethyl benzyl group Chemical group 0.000 description 1
- 206010044652 trigeminal neuralgia Diseases 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 239000000085 vanilloid receptor antagonist Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- FVECELJHCSPHKY-JLSHOZRYSA-N veratridine Chemical compound C1=C(OC)C(OC)=CC=C1C(=O)O[C@@H]1[C@@]2(O)O[C@]34C[C@@]5(O)[C@H](CN6[C@@H](CC[C@H](C)C6)[C@@]6(C)O)[C@]6(O)[C@@H](O)C[C@@]5(O)[C@@H]4CC[C@H]2[C@]3(C)CC1 FVECELJHCSPHKY-JLSHOZRYSA-N 0.000 description 1
- 230000009278 visceral effect Effects 0.000 description 1
- 108010078375 voltage-dependent calcium channel (P-Q type) Proteins 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 230000002034 xenobiotic effect Effects 0.000 description 1
- 230000022814 xenobiotic metabolic process Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
- C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4453—Non condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/14—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
- C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
- C07D265/36—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings condensed with one six-membered ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/195—Radicals derived from nitrogen analogues of carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/26—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/14—The ring being saturated
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Nutrition Science (AREA)
- Otolaryngology (AREA)
- Diabetes (AREA)
- Reproductive Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Indole Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Description
WO 2007/071311は、電位依存性カルシウム及び/またはナトリウムチャネルの機能不全に起因する障害に対するカルシウム及び/またはナトリウムチャネルモジュレーターとして活性な薬剤を製造するために使用される電位依存性カルシウム及び/またはナトリウムチャネルモジュレーターとしての一般式I
(a)
Jはエチルアミノ鎖に対してパラ位にある基Α−[(CH2)n−O]r−であり、ここでnは0または1であり、rは1であり、Aはトリフルオロメチル;シクロペンチル;または場合によりハロ基で置換されているフェニルであり、
Wは(C1−C4)アルコキシであり、
Rは水素であり、
R0は水素または(C1−C2)アルキルであり、
R1は水素;場合によりヒドロキシ基で置換されている(C1−C4)アルキル;シクロプロピルメチル;2−プロピン−1−イル;場合によりベンゼン環上で1または2個の(C1−C2)アルコキシ基で置換されているベンジル;チアゾリル;窒素原子を含有し、場合により(C1−C2)アルキル基で置換されている5〜6員の飽和ヘテロシクリル;またはヘテロシクリル基が窒素、酸素及び硫黄から選択される1〜3個のヘテロ原子を含有している5〜6員のヘテロシクリルであり、場合により(C1−C2)アルキル、ヒドロキシメチル及び(C1−C2)アルコキシから選択される1〜2個の基で置換されているヘテロシクリルメチルであり、
R2は水素、(C1−C4)アルキルまたはフェニルであり、
R3は水素または(C1−C4)アルキルであり、
R4は水素;場合によりアミノ、(C1−C4)アルキルアミノ、ジ−(C1−C4)アルキルアミノ、イミダゾリル及びピロリジニルから選択される基で置換されている(C1−C4)アルキル、ここで前記イミダゾリル及びピロリジニル基は場合により(C1−C2)アルキル基で置換されている;またはベンジルであり、或いは
R3及びR4は隣接窒素原子と一緒に場合により(C1−C2)アルキル基で置換されているピロリジニル、モルホリニルまたはピペラジニル環を形成する;または
(b)
Jはエチルアミノ鎖に対してパラ位にある基A−[(CH2)n−O]r−であり、
ここで、
nは1であり、
rは1であり、
Aはフェニル;またはハロ基で置換されているフェニルであり、
Wは水素であり、
Rは水素であり、
R0は(C1−C2)アルキルであり、
R1は水素であり、
R2は(C1−C2)アルキルであり、
R3は水素または(C1−C4)アルキルであり、
R4は水素または(C1−C4)アルキルである;または
(c)
Jは水素であり、
Wは基A−[(CH2)n−O]r−であり、ここで
nは0、1または2であり、
rは0または1であり、
Aは(C1−C4)アルキル;トリフルオロメチル;シクロプロピル;シクロペンチル;場合によりハロ、メチル、メトキシ、トリフルオロメチル、アセチルアミノ及びジメチルアミノメチルから選択される基で置換されているフェニル;場合によりクロロ基で置換されているチエニル;フラニル;場合により1または2個のメチル基で置換されているイソオキサゾリル;ピペリジニル;モルホリニル;ピリジニルまたはピリミジニルであり、前記したピリジニル及びピリミジニル環は場合により1または2個のメトキシ基で置換されており、
Rは水素またはフルオロであり、
R0は水素または(C1−C2)アルキルであり、
R1はイソプロピル、シクロプロピルメチル、フラニルメチル、テトラヒドロフラニルまたはテトラヒドロフラニルメチルであり、
R2は水素または(C1−C4)アルキルであり、
R3は水素または(C1−C4)アルキルであり、
R4は水素;場合により(C1−C2)アルコキシ、アミノ、(C1−C4)アルキルアミノ及びジ−(C1−C4)アルキルアミノから選択される基で置換されている(C1−C4)アルキル;ヘテロシクリルがイソオキサゾリル、ピラゾリル、イミダゾリル、チアゾリル及び1,3,4−チアジアゾリルから選択され、場合により(C1−C2)アルキル基で置換されていてもよいヘテロシクリルであり、または
R3及びR4は隣接窒素原子と一緒にピロリジン環を形成し、
ただしAが(C1−C4)アルキル、トリフルオロメチル、シクロプロピルまたはシクロペンチルのときには、rは1であり、更にR1がイソプロピルのときには、Aはトリフルオロメチルであり、nは1である)
の置換2−フェニルエチルアミノ誘導体を記載している。
Xは−O−、−S−または−SO2−であり、
Yは水素、OHまたはO(C1−C4)アルキル、
Zは=Oまたは=Sであり、
Rは(C3−C10)アルキル、ω−トリフルオロ(C3−C10)アルキルであり、
R1及びR2は独立して水素、ヒドロキシ、(C1−C8)アルコキシ、(C1−C8)アルキルチオ、ハロ、トリフルオロメチルまたは2,2,2−トリフルオロエチルであり、またはR1及びR2の1つはR−X−に対してオルト位にあり、同じR−X−と一緒に
を表し、
R3及びR’3は独立して水素または(C1−C4)アルキルであり、
R4及びR5は独立して水素、(C1−C4)アルキルであり、またはR4は水素であり、R5は−CH2−OH、−CH2−O−(C1−C6)アルキル、−CH(CH3)−OH、−(CH2)2−S−CH、ベンジル及び4−ヒドロキシベンジルから選択される基であり、または R4及びR5は隣接炭素原子と一緒に(C3−C6)シクロアルキル残基を形成し、
R6及びR7は独立して水素または(C1−C6)アルキルであり、または隣接窒素原子と一緒に場合により−O−、−S−及び−NR8−から選択される1個の追加ヘテロ原子を含有している5〜6員の単環式飽和ヘテロ環を形成し、ここでR8は水素または(C1−C6)アルキルであり、
ただしXが−S−または−SO2−のときにはYはOHでもO(C1−C4)アルキルでもない)
の置換2−[2−(フェニル)−エチルアミノ]アルカンアミド誘導体及びその医薬的に許容され得る塩を記載している。
ナトリウムチャネルは、電気インパルスを細胞及び細胞ネットワーク中に迅速に伝達し、よって運動から認識までの範囲のより高いプロセスを調整することにより神経ネットワークにおいて重要な役割を発揮する。これらのチャネルは大きな膜貫通タンパク質であり、ナトリウムイオンに対する選択的透過性を可能にするように異なる生物物理的状態間を切り換えることができる。このプロセスを生じさせるためには、膜を脱分極させるために活動電位が必要であり、よってこれらのチャネルは電位依存性である。
・低代謝者−これらの被験者はCYP2D6機能を全くまたは殆ど有していない。
・中間代謝者−これらの被験者は低代謝者と高代謝者の間の速度で薬物を代謝する。
・高代謝者−これらの被験者は正常なCYP2D機能を有している。
・超迅速代謝−これらの被験者は発現されたCYP2D6遺伝子の複数のコピーを有し、従って正常以上のCYP2D6機能を有している。
Wは基A−[(CH2)m−O]−であり、ここでmは0、1、2または3であり、Aは場合により1〜3個のフッ素原子で置換されている(C1−C4)アルキル;(C3−C6)シクロアルキル;場合によりハロ、メチル、メトキシ、トリフルオロメチル、アセチルアミノ及びジメチルアミノメチルから選択される基で置換されているフェニル;場合によりクロロ基で置換されているチエニル;フラニル;イソオキサゾリル;チアゾリル;ピペリジニル;モルホリニル;ピリジニルまたはピリミジニルであり、前記したピリジニル及びピリミジニル環は場合により1または2個のメトキシ基で置換されており、
Jは独立して水素、(C1−C4)アルキル、(C1−C4)アルコキシまたはハロ基であり、
nは1または2であり、
R1は水素;場合によりヒドロキシ基または(C1−C4)アルコキシ基で置換されている(C1−C4)アルキル;または(C3−C8)シクロアルキルであり、
R2及びR2’は独立して水素;場合により(C1−C4)アルコキシ基で置換されている(C1−C4)アルキル;場合により(C1−C4)アルキル、(C1−C4)アルコキシまたはハロ基で置換されているフェニル;場合によりベンゼン環上で(C1−C4)アルキル、(C1−C4)アルコキシまたはハロ基で置換されているベンジルであり、或いは
R2及びR2’は隣接炭素原子と一緒に(C3−C6)シクロアルキリデン基を形成し、
R3は水素または(C1−C4)アルキルであり、
R4は水素、(C1−C4)アルキル、フェニル、シクロヘキシルまたはベンジルであり、或いは
R3及びR4は隣接窒素原子と一緒にアゼチジニル、ピロリジニル、モルホリニル、ピペリジニルまたはピペラジニル環、前記ピペリジニル環は場合により1または2個の(C1−C2)アルキル基で置換されており、前記ピペラジニル環は場合により他のN原子上で(C1−C4)アルキル、ベンジルまたはフェニルスルホニル基で置換されている;またはベンゼン環と縮合したピロリジニル、ピペリジニル、モルホリニルまたはピペラジニル環を形成し、
R5は水素またはフルオロであり、
R6はフルオロである)
の化合物及びその医薬的に許容され得る塩である。
Wが基A−[(CH2)m−O]−であり、ここでmは0、1、2または3であり、Aが場合により1〜3個のフッ素原子で置換されている(C1−C4)アルキル;(C3−C6)シクロアルキル;場合によりハロ基で置換されているフェニル;またはチアゾリルであり、
Jが独立して水素、C1−C4アルキル、クロロまたはフルオロであり、
nが1または2であり、
R1が水素;場合によりヒドロキシ基または(C1−C4)アルコキシ基で置換されている(C1−C4)アルキル;または(C3−C6)シクロアルキルであり、
R2が水素または(C1−C4)アルキルであり、
R2’が水素;または場合により(C1−C4)アルコキシまたはフェニル基で置換されている(C1−C4)アルキルであり、前記フェニル基は場合により(C1−C4)アルコキシ基で置換されており、
R3が水素または(C1−C4)アルキルであり、
R4が水素、(C1−C4)アルキル、フェニルまたはシクロヘキシルであり、或いは
R3及びR4が隣接窒素原子と一緒にアゼチジニル、ピロリジニル、モルホリニル、ピペリジニルまたはピペラジニル、前記ピペリジニル環は場合により1または2個の(C1−C2)アルキル基で置換されており、前記ピペラジニル環は場合により他のN原子上で(C1−C4)アルキル、ベンジルまたはフェニルスルホニル基で置換されている;またはベンゼン環と縮合したピロリジニル、ピペリジニル、モルホリニルまたはピペラジニル環を形成し、
R5が水素またはフルオロであり、
R6がフルオロである
化合物及びその医薬的に許容され得る塩を含む。
Wが基A−[(CH2)m−O]−であり、ここでmは1または2であり、Aは場合により1〜3個のフッ素原子で置換されている(C1−C4)アルキル;場合によりクロロまたはフルオロ基で置換されているフェニル;またはチアゾリルであり、
Jが独立して水素、メチルまたはフルオロであり、
nが1〜2であり、
R1が水素;場合によりヒドロキシ基または(C1−C4)アルコキシ基で置換されている(C1−C4)アルキルであり、
R2が水素またはメチルであり、
R2’が水素;場合によりメトキシまたはフェニル基で置換されている(C1−C4)アルキルであり、前記フェニル基は場合によりメトキシ基で置換されており、
R3が水素または(C1−C4)アルキルであり、
R4が水素、(C1−C4)アルキル、フェニル、またはシクロヘキシルであり、或いは
R3及びR4が隣接窒素原子と一緒にアゼチジニル、ピロリジニル、モルホリニル、ピペリジニルまたはピペラジニル環、前記ピペリジニル環は場合により1または2個のメチル基で置換されており、前記ピペラジニル環は場合により他のN原子上でメチル、ベンジルまたはフェニルスルホニル基で置換されている;またはベンゼン環と縮合したピロリジニル、ピペリジニル、モルホリニルまたはピペラジニル環を形成し、
R5が水素またはフルオロであり、
R6がフルオロである
化合物及びその医薬的に許容され得る塩を含む。
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−N,N−ジメチル−アセトアミド(実施例1−1)、
2−[2,2−ジフルオロ−2−(3−ペンチルオキシフェニル)−エチルアミノ]−N,N−ジメチル−アセトアミド(実施例1−2)、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−N,N−ジプロピル−アセトアミド(実施例1−3)、
2−[2,2−ジフルオロ−2−(3−ブトキシ−4−メチルフェニル)−エチルアミノ]−N,N−ジメチル−アセトアミド(実施例1−4)、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−N,N−ジブチル−アセトアミド(実施例1−5)、
2−[2,2−ジフルオロ−2−(3−ヘキシルオキシフェニル)−エチルアミノ]−N,N−ジメチル−アセトアミド(実施例1−6)、
2−{2,2−ジフルオロ−2−[3−(4,4,4−トリフルオロブトキシ)−フェニル]−エチルアミノ}−N,N−ジメチル−アセトアミド(実施例1−7)、
2−[2,2−ジフルオロ−2−(3−ペンチルオキシフェニル)−エチルアミノ]−N,N−ジプロピル−アセトアミド(実施例1−8)、
2−{2,2−ジフルオロ−2−[3−(3−(3−フルオロフェニル)−プロポキシ)−フェニル]−エチルアミノ}−N,N−ジメチル−アセトアミド(実施例1−9)、
2−{2,2−ジフルオロ−2−[3−(3−(3−クロロフェニル)−プロポキシ)−フェニル]−エチルアミノ}−N,N−ジメチル−アセトアミド(実施例1−10)、
2−[2,2−ジフルオロ−2−(3−ブトキシ−2−フルオロフェニル)−エチルアミノ]−N,N−ジメチル−アセトアミド(実施例1−11)、
2−{2,2−ジフルオロ−2−[3−(3−フェニルプロポキシ)−フェニル]−エチルアミノ}−N,N−ジメチル−アセトアミド(実施例1−12)、
2−{2,2−ジフルオロ−2−[3−(3−チアゾル−2−イル−プロポキシ)−フェニル]−エチルアミノ}−N,N−ジメチル−アセトアミド(実施例1−13)、
2−[2,2−ジフルオロ−2−(3−ベンジルオキシフェニル)−エチルアミノ]−N,N−ジメチル−アセトアミド(実施例1−14)、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−1−(ピロリジン−1−イル)−エタノン(実施例1−15)、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−N−メチル−N−フェニル−アセトアミド(実施例1−16)、
2−{2,2−ジフルオロ−2−[3−(3−フェニルプロポキシ)−フェニル]−エチルアミノ}−1−(ピロリジン−1−イル)−エタノン(実施例1−17)、
2−{2,2−ジフルオロ−2−[3−(4,4,4−トリフルオロブトキシ)−フェニル]−エチルアミノ}−1−(ピロリジン−1−イル)−エタノン(実施例1−18)、
2−[2,2−ジフルオロ−2−(3−ベンジルオキシフェニル)−エチルアミノ]−1−(モルホリン−4−イル)−エタノン(実施例1−19)、
2−{2,2−ジフルオロ−2−[3−(3−フェニルプロポキシ)−フェニル]−エチルアミノ}−1−(モルホリン−4−イル)−エタノン(実施例1−20)、
2−{2,2−ジフルオロ−2−[3−(4,4,4−トリフルオロブトキシ)−フェニル]−エチルアミノ}−1−(モルホリン−4−イル)−エタノン(実施例1−21)、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−1−(2H−ベンゾ[b][1,4]オキサジン−4(3H)−イル)−エタノン(実施例1−22)、
2−[2,2−ジフルオロ−2−(3−ベンジルオキシフェニル)−エチルアミノ]−1−(ピロリジン−1−イル)−エタノン(実施例1−23)、
2−{2,2−ジフルオロ−2−[3−(3−フェニルプロポキシ)−フェニル]−エチルアミノ}−N−メチル−N−フェニル−アセトアミド(実施例1−24)、
2−{2,2−ジフルオロ−2−[3−(4,4,4−トリフルオロブトキシ)−フェニル]−エチルアミノ}−N−メチル−N−フェニル−アセトアミド(実施例1−25)、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−1−(4−メチルピペラジン−1−イル)−エタノン(実施例1−26)、
2−{2,2−ジフルオロ−2−[3−(3−フェニルプロポキシ)−フェニル]−エチルアミノ}−1−(4−メチルピペラジン−1−イル)−エタノン(実施例1−27)、
2−{2,2−ジフルオロ−2−[3−(4,4,4−トリフルオロブトキシ)−フェニル]−エチルアミノ}−1−(4−メチルピペラジン−1−イル)−エタノン(実施例1−28)、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−1−(ピペリジン−1−イル)−エタノン(実施例1−29)、
2−{2,2−ジフルオロ−2−[3−(3−フェニルプロポキシ)−フェニル]−エチルアミノ}−1−(ピペリジン−1−イル)−エタノン(実施例1−30)、
2−{2,2−ジフルオロ−2−[3−(4,4,4−トリフルオロブトキシ)−フェニル]−エチルアミノ}−1−(ピペリジン−1−イル)−エタノン(実施例1−31)、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−N,N−ジエチル−アセトアミド(実施例1−32)、
2−{2,2−ジフルオロ−2−[3−(2−フルオロベンジルオキシ)−フェニル]−エチルアミノ}−N,N−ジメチル−アセトアミド(実施例1−33)、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−1−(シス−3,5−ジメチルピペリジン−1−イル)−エタノン(実施例1−35)、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−1−(3,4−ジヒドロイソキノリン−2(1H)−イル)−エタノン(実施例1−35)、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−N,N−ジイソプロピル−アセトアミド(実施例1−36)、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−N−シクロヘキシル−N−メチル−アセトアミド(実施例1−37)、
2−[2,2−ジフルオロ−2−(3−ベンジルオキシフェニル)−エチルアミノ]−1−(ピペリジン−1−イル)−エタノン(実施例1−38)、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−1−[4−(フェニルスルホニル)−ピペラジン−1−イル]−エタノン(実施例1−39)、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−1−(インドリン−1−イル)−エタノン(実施例1−40)、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−1−(4−ベンジルピペラジン−1−イル)−エタノン(実施例1−41)、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−1−(アゼチジン−1−イル)−エタノン(実施例1−42)、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−N,N−ジメチル−プロパンアミド(実施例2−1)、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−3−メトキシ−N,N−ジメチル−プロパンアミド(実施例2−2)、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−3−(4−メトキシフェニル)−N,N−ジメチル−プロパンアミド(実施例2−3)、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−2−N,N−トリメチル−プロパンアミド(実施例2−4)、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−4−N,N−トリメチル−ペンタンアミド(実施例2−5)、
2−{[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチル]−メチルアミノ}−N,N−ジメチル−アセトアミド(実施例3−1)、
2−{[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチル]−(3−メトキシプロピル)−アミノ}−N,N−ジメチル−アセトアミド(実施例3−2)、
2−{[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチル]−(2−メトキシエチル)−アミノ}−N,N−ジメチル−アセトアミド(実施例3−3)、
2−[2−フルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−N,N−ジメチル−アセトアミド(実施例4−1)、
2−{2−フルオロ−2−[3−(3−クロロベンジルオキシ)−フェニル]−エチルアミノ}−N,N−ジメチル−アセトアミド(実施例4−2)、
2−{2−フルオロ−2−[3−(3−フルオロベンジルオキシ)−フェニル]−エチルアミノ}−N,N−ジメチル−アセトアミド(実施例4−3)
からなる群から選択され、場合により単離された形態の単一光学異性体としてまたは任意の比率のその混合物であり、及びその医薬的に許容され得る塩である。
a)式II
の化合物を得る;
c)式IVの化合物のアミノ基を適当な保護剤、例えばジ−tert−ブトキシ−ジカーボネートで保護して、式V
の適当なハロアルキルアミドと反応させて、R1が水素である式Iの化合物を得る
ことを含む合成方法に従って製造される。
の化合物を、塩基の存在下で化合物R1−Z(ここで、R1は水素を除いて上に記載されている意味を有し、Zはハロゲン原子または良好な離脱基、例えばメタンスルホニルオキシ、p−トルエンスルホニルオキシまたはトリフルオロメタンスルホニルオキシである)と反応させること、または還元剤の存在下で式R7R8CO(ここで、R7及びR8は両方水素を表し、または隣接カルボニル基と一緒に場合によりヒドロキシル基または(C1−C4)アルコキシ基で置換されている(C2−C4)脂肪族アルデヒドまたは(C3−C4)脂肪族ケトンを表し、或いはR7及びR8は隣接カルボニル基と一緒に(C3−C6)脂環式ケトンを表す)のカルボニル化合物と反応させることにより製造され得る。
本発明の化合物は、CYP2D6阻害作用が実質的にないことまたは有意に低いCYP2D6阻害作用を示すことを特徴とし、電位依存性カルシウム及び/またはナトリウムチャネルの機能不全に起因する障害に対するナトリウム及び/またはカルシウムチャネルモジュレーターとして活性な薬剤を製造するために使用され得る。
1H−NMRスペクトルはCDCl3またはDMSO−d6の溶液中Varian Gemini 200MHz分光計を用いて保存する。化学シフトは内部標準としてCDCl3またはDMSO−d6及びD2Oを用いてδとして規定する。
DCM:ジクロロメタン
EtAc:酢酸エチル
THF:テトラヒドロフラン
PE:石油エーテル
DMF:ジメチルホルムアミド
DMSO:ジメチルスルホキシド
DIPEA:ジイソプロピルエチルアミン
NaH:水素化ナトリウム
LiAlH4:水素化アルミニウムリチウム
LC/MS:液体クロマトグラフィー/質量分光法
TLC:薄層クロマトグラフィー
RT:室温
Boc2O:ジ−tert−ブチルジカーボネート
MW:314.36
質量電荷比:315.36(MH+,ESI pos,3.2KV,25V,350℃)
1H−NMR(300MHz,DMSO−d6)δ ppm 9.58(bs,2H),7.47(t,1H),6.98−7.29(m,3H),4.08(s,2H),4.04(t,2H),3.86(t,2H),2.93(s,3H),2.91(s,3H),1.62−1.82(m,2H),1.34−1.54(m,2H),0.95(t,3H)。
2−(3−メトキシフェニル)アセトニトリル(2g;13.59mmol)を乾燥DCM(13mL)中に含む0℃に冷却された溶液に窒素雰囲気下、DCM中BBr3の1M溶液(28.54mmol;28.54mL)をゆっくり1滴ずつ添加する。混合物を室温で20時間撹拌する。次いで、反応混合物を氷に注ぎ、水を添加し、有機相をDCMで3回抽出し、ブラインで洗浄し、無水Na2SO4で乾燥する。蒸発後、粗な混合物をシリカゲルで溶離液としてPE/EtAc(80/20)を用いるクロマトグラフィーにかけて、1.28g(71%)の2−(3−ヒドロキシフェニル)アセトニトリルを得る。
2−(3−ヒドロキシフェニル)アセトニトリル(2.29g;17.11mmol)を乾燥DMF(25mL)中に含む溶液に、K2CO3(7.08g;51.33mmol)、KI(0.61g;3.70mmol)及び1−ブロモブタン(4.69g;3.69mL;34.22mmol)を添加し、混合物を60℃で5時間、次いで室温で一晩撹拌する。反応混合物をEtAc(150mL)で抽出し、ブライン(150mL)で洗浄する。水性相を0.1N HClで酸性化し、酢酸エチルで再び抽出する。合わせた有機相を無水Na2SO4で乾燥し、濾過し、蒸発させる。粗な混合物をフラッシュクロマトグラフィー(溶離液:PE/EtAc 99/1)により精製し、蒸発後、3.07g(95%)の2−(3−ブトキシフェニル)アセトニトリルを得る。
2−(3−ブトキシフェニル)アセトニトリル(903mg;4.80mmol)を乾燥THF(75mL)中に含む溶液を−78℃で冷却し、−75℃〜−78℃の内部温度を維持しながらtert−ブチルリチウム(ペンタン中1.6M;6.6mL;10.56mmol)を1滴ずつ添加する。溶液を−78℃で10分間撹拌した後、N−フルオロベンゼンスルホンイミド(N−FSI;3.78g;12.00mmol)を乾燥THF(12mL)中に含む溶液を15分以内に添加する。反応混合物を−78℃で2時間撹拌した後、−78℃で0.01N HClでクエンチし、室温とする。次いで、酢酸エチル(50mL)を添加し、混合物を蒸発させる。1.79gのベンゼンスルホンイミド副生成物沈殿物(白色固体)を濾別する。溶液をブラインで洗浄し、無水Na2SO4で乾燥する。蒸発後、粗な残渣をフラッシュクロマトグラフィー(溶離液:石油エーテル/酢酸エチル 99.5/0.5、次いで石油PE/EtAc 99/1)にかけて、559mg(52%)の純粋な2,2−ジフルオロ−[2−(3−メトキシフェニル)]アセトニトリル及び355mgの更に精製すべき同一生成物を得る。
AlCl3(400mg;3.00mmol)を乾燥エチルエーテル(6mL)中に含む溶液を0℃で30分間撹拌する。前記混合物にLiAlH4の予冷した(0℃)懸濁液(THF中1M;3.00mL;3.00mmol)を添加する。5分後、2,2−ジフルオロ−[2−(3−メトキシフェニル)]アセトニトリルを乾燥THF(9mL)中に含む予冷した(0℃)溶液を添加する。0℃で2時間後、反応が完了する。溶液を数滴の飽和NaHCO3でクエンチし、EtAcで3回抽出し、無水Na2SO4で乾燥し、濾過し、蒸発させる。2,2−ジフルオロ−2−(3−ブトキシフェニル)エチルアミン(587mg)が得られ、以下のステップEにおいて粗な残渣として使用する。
乾燥THF(41mL)中の2,2−ジフルオロ−2−(3−ブトキシフェニル)エチルアミン(509mg;2.22mmol)を室温で撹拌しながら、ジ−tert−ブチルジカーボネート(Boc2O)及びEt3Nを添加する。混合物を室温で24時間撹拌する。溶媒を蒸発させ、粗な残渣を溶離液としてPE/EtAc 97/3を用いるフラッシュクロマトグラフィーにより精製する。N−(tert−ブトキシカルボニル)−2,2−ジフルオロ−2−(3−ブトキシフェニル)エチルアミンをオフホワイト色固体(481mg、66%)として得た。
N−(tert−ブトキシカルボニル)−2,2−ジフルオロ−2−(3−ブトキシフェニル)エチルアミン(150mg;0.46mmol)を乾燥DMF(2.5mL)中に溶解し、溶液を0℃に冷却した。NaH(鉱油中60%;22mg;0.55mmol)を添加し、反応混合物を0℃で10分間、更に室温で10分間撹拌する。反応混合物を再び0℃で冷却した後、N,N−ジメチルクロロアセトアミド(73mg;0.60mmol)を添加し、撹拌を室温で24時間継続する。反応物を水でクエンチし、EtAcで3回抽出し、ブラインで洗浄する。有機相を無水Na2SO4で乾燥し、濾過し、蒸発させる。残渣をシリカゲルでフラッシュクロマトグラフィー(溶離液:DCM/EtAc,98/2から95/5)にかける。2−[N−(tert−ブトキシカルボニル)−2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−N,N−ジメチル−アセトアミド(165mg;87%)を白色固体として得る。
2−[N−(tert−ブトキシカルボニル)−2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−N,N−ジメチル−アセトアミド(160mg;0.39mmol)をDCM(5mL)中に溶解した後、ジオキサン中4M HCl(0.6mL;2.4mmol)を添加し、反応混合物を一晩放置する。更に、ジオキサン中4M HCl(0.2mL;2eq)(全部で0.8mL)を添加し、混合物を一晩撹拌する。溶媒を蒸発させ、ジエチルエーテルを添加した後、蒸発させて、139mg(100%)の白色固体2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−N,N−ジメチル−アセトアミド塩酸塩(実施例1−1)を得る。
これらの化合物は適当な試薬を用いてスキーム1に記載されている同一手順に従って製造される。
MW:328.41
質量電荷比:329.25(MH+,ESI pos,3.2KV,25V,350℃)
1H−NMR(300MHz,DMSO−d6)δ ppm 9.37(bs,2H),7.47(t,1H),7.02−7.24(m,3H),4.06(s,2H),4.03(t,2H),3.83(t,2H),2.93(s,3H),2.90(s,3H),1.74(q,2H),1.28−1.50(m,2H),0.91(t,3H)。
MW:370.49
質量電荷比:371.10(MH+,ESI pos,3.2KV,25V,350℃)
1H−NMR(300MHz,DMSO−d6)δ ppm 8.84(bs,2H),7.48(t,1H),7.02−7.26(m,3H),4.03(s,2H),3.94(s,2H),3.78(t,2H),3.21−3.29(m,2H),3.06−3.19(m,2H),1.64−1.79(m,2H),1.37−1.61(m,2H),0.95(t,3H),0.86(t,3H),0.64(t,3H)。
MW:328.41
質量電荷比:329.08(MH+,ESI pos,3.2KV,25V,350℃)
1H−NMR(300MHz,DMSO−d6)δ ppm 9.44(bs,2H),7.15−7.17(tdd,3H),4.03(s,2H),4.03(t,2H),3.81(s,2H),3.09(s,2H),2.80(s,3H),2.78(s,3H),2.13(s,3H),1.77(tt,2H),1.40(tq,2H),0.88(t,3H)。
MW:342.43
質量電荷比:343.31(MH+,ESI pos,3.2KV,25V,350℃)
1H−NMR(300MHz,DMSO−d6)δ ppm 9.47(bs,2H),7.47(t,1H),7.03−7.24(m,3H),4.03(s,2H),3.84(t,2H),3.83(s,2H),2.93(s,3H),2.90(s,3H),1.64−1.81(m,2H),1.36−1.54(m,2H),1.22−1.37(m,4H),0.89(t,3H)。
MW:368.35
質量電荷比:369.20(MH+,ESI pos,3.2KV,25V,400℃)
1H−NMR(300MHz,DMSO−d6)δ ppm 9.41(bs,2H),7.43−7.58(m,1H),6.99−7.29(m,3H),4.11(t,2H),4.06(t,2H),3.84(t,2H),2.93(s,3H),2.90(s,3H),2.31−2.48(m,2H),1.86−2.09(m,2H),1.22−1.37(m,4H),0.89(t,3H)。
MW:384.51
質量電荷比:385.22(MH+,ESI pos,3.2KV,25V,350℃)
1H−NMR(300MHz,DMSO−d6)δ ppm 8.82(bs,1H),7.48(t,1H),7.03−7.29(m,3H),4.04(s,2H),3.91(s,2H),3.80(t,2H),3.21−3.28(m,2H),3.06−3.19(m,2H),1.64−1.79(m,2H),1.37−1.61(m,4H),0.92(t,3H),0.87(t,3H),0.63(t,3H)。
MW:348.40
質量電荷比:349.22(MH+,ESI pos,3.2KV,15V,400℃)
1H−NMR(300MHz,DMSO−d6)δ ppm 9.40(bs,1H),7.29−7.60(m,6H),7.09−7.29(m,3H),5.18(s,2H),4.04(s,2H),3.83(t,2H),2.93(s,3H),2.90(s,3H)。
MW:340.42
質量電荷比:341.02(MH+,ESI pos,3.2KV,25V,400℃)
1H−NMR(300MHz,DMSO−d6)δ ppm 9.34(bs,1H),7.47(t,1H),7.07−7.21(m,3H),4.03(t,2H),3.94(s,2H),3.84(t,2H),3.36(t,4H),1.85−2.01(m,2H),1.76−1.85(m,2H),1.64−1.76(m,2H),1.45(m,2H),0.95(t,3H)。
MW:394.39
質量電荷比:395.23(MH+,ESI pos,3.2KV,25V,400℃)
1H−NMR(300MHz,DMSO−d6)δ ppm 9.48(bs,2H),7.35−7.61(m,1H),7.01−7.26(m,3H),4.11(t,2H),3.96(s,2H),3.86(t,2H),3.28−3.40(m,4H),2.33−2.48(m,2H),1.68−2.04(m,6H)。
MW:410.39
質量電荷比:411.22(MH+,ESI pos,3.2KV,15V,400℃)
1H−NMR(300MHz,DMSO−d6)δ ppm 9.70(bs,2H),7.50(t,1H),6.88−7.37(m,3H),4.15(s,2H),4.12(t,2H),3.87(t,2H),3.54−3.67(m,4H),3.44−3.54(m,2H),3.32−3.44(m,2H),2.32−2.47(m,2H),1.86−2.06(m,2H)。
MW:369.46
質量電荷比:370.07(MH+,ESI pos,3.2KV,15V,400℃)
1H−NMR(300MHz,DMSO−d6)δ ppm 7.28−7.49(m,1H),6.92−7.18(m,3H),4.04(t,2H),3.62−3.85(m,1H),3.52(s,2H),3.32(t,2H),2.87−3.19(m,8H),2.69(s,3H),1.61−1.84(m,2H),1.48(dq,2H),0.96(t,3H)。
MW:423.43
質量電荷比:424.28(MH+,ESI pos,3.2KV,25V,400℃)
1H−NMR(300MHz,DMSO−d6)δ ppm 11.56(bs,1H),9.57(bs,1IH),7.37−7.60(m,1H),6.99−7.28(m,3H),4.29−4.59(m,1H),4.16−4.30(m,1H),4.11(t,2H),3.80(t,2H),2.87−3.94(m,8H),2.77(s,3H),2.33−2.47(m,2H),1.85−2.06(m,2H)。
MW:354.44
質量電荷比:355.03(MH+,ESI pos,3.2KV,15V,400℃)
1H−NMR(300MHz,DMSO−d6)δ ppm 9.37(bs,2H),7.47(t,1H),7.04−7.21(m,3H),4.07(s,2H),3.84(t,2H),3.45−3.54(m,2H),3.21−3.32(m,2H),1.66−1.81(m,2H),1.33−1.66(m,8H),0.95(t,3H)。
MW:342.43
質量電荷比:343.05(MH+,ESI pos,3.2KV,15V,350℃)
1H−NMR(300MHz,DMSO−d6)δ ppm 7.47(t,1H),7.07−7.20(m,3H),4.03(t,2H),4.02(s,2H),3.84(t,2H),3.34(q,2H),3.24(q,2H),1.64−1.82(m,2H),1.36−1.55(m,2H),1.12(t,3H),1.07(t,3H),0.95(t,3H)。
MW:326.39
質量電荷比:327.13(MH+,ESI pos,3.2KV,25V,400℃)
1H−NMR(300MHz,DMSO−d6)δ ppm 7.31−7.46(m,1H),6.95−7.13(m,3H),4.01(t,4H),3.84(t,2H),3.14−3.24(m,2H),3.104(dq,2H),2.18(dt,2H),1.63−1.79(m,2H),1.45(dq,2H),0.94(t,3H)。
MW:328.41
質量電荷比:329.02(MH+,ESI pos,3.2KV,25V,350℃)
1H−NMR(300MHz,DMSO−d6)δ ppm 9.48(bs,1H),7.47(t,1H),7.04−7.24(m,3H),4.24−4.51(m,1H),4.03(t,2H),3.71−3.95(m,1H),3.51−3.71(m,1H),2.98(s,3H),2.89(s,3H),1.62−1.82(m,2H),1.42(d,3H),1.34−1.54(m,2H),0.95(t,3H)。
N−tert−ブトキシカルボニル−2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミン(75mg;0.23mmol)を乾燥DMF(5mL)中に溶解する。溶液を0℃に冷却し、NaH(6.7mg;1.2eq)を添加する。溶液を室温で10分間撹拌した後、再び0℃に冷却し、2−クロロ−N,N−ジメチルプロパンアミド(31mg;0.23mmol)を添加する。4時間後、更にNaH(6.7mg;1.2eq)を添加する。反応混合物を室温で一晩撹拌した後、水でクエンチし、蒸発させ、残渣を水及びEtAcに取る。有機層を分離し、水層をEtAcで3回抽出する。合わせた有機相を無水Na2SO4で乾燥し、濾過し、蒸発させる。生じた粗な残渣をフラッシュクロマトグラフィー(溶離液:石油エーテル/EtAc,9/1〜8/2)にかける。2−[N−tert−ブトキシカルボニル−2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−N,N−ジメチルプロパンアミド(84mg;81%)を薄黄色油状物として得る。
2−[N−tert−ブトキシカルボニル−2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−N,N−ジメチルプロパンアミド(84mg;0.196mmol)をDCM(3mL)中に溶解し、ジオキサン中4M HCl溶液(0.49mL;1.96mmmol;10eq)を添加する。8時間後、更にジオキサン中4M HCl(0.49mL;10eq)を添加し、混合物を一晩撹拌する。更にジオキサン中4M HCl(0.245mL;5eq)を添加し、混合物を更に24時間撹拌する。溶液を蒸発させ、白色残渣をジエチルエーテル中に懸濁した後、2回蒸発させる。残渣をシリカゲルでフラッシュクロマトグラフィー(溶離液としてDCM/MeOH 1/1、次にMeOH/濃NH3 95/5)にかけ、遊離塩基2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−N,N−ジメチルプロパンアミドを薄黄色流体として単離する。化合物をDCM(3mL)中に溶解し、ジオキサン中4M HClを添加して、溶液をpH2とする。混合物を10分間撹拌した後、蒸発させる。白色残渣をエーテルに取り、2回蒸発させる。45mg(49%)の2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−N,N−ジメチルプロパンアミド塩酸塩(実施例2−1)を得る。
これらの化合物はスキーム2に記載されている手順に従って製造される:
実施例2−2:2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−3−メトキシ−N,N−ジメチル−プロパンアミド
MW:358.43
質量電荷比:359.40(MH+,ESI pos,3.2KV,15V,400℃)
1H−NMR(300MHz,DMSO−d6)δ ppm 7.39−7.59(m,1H),7.06−7.21(m,3H),4.64(t,1H),4.03(t,2H),3.58−3.87(m,4H),3.30(s,3H),3.02(s,3H),2.91(s,3H),1.59−1.81(m,2H),1.36−1.57(m,2H),0.94(t,3H)。
MW:328.41
質量電荷比:329.17(MH+,ESI pos,3.2KV,25V,400℃)
1H−NMR(300MHz,DMSO−d6)δ ppm 7.45(t,1H),7.04−7.18(m,3H),4.03(t,2H),3.73−3.91(m,2H),3.70−4.13(m,2H),2.86(s,3H),2.84(s,3H),2.80(s,3H),1.62−1.82(m,2H),1.37−1.57(m,2H),0.94(t,3H)。
これらの化合物はスキーム3に記載されている手順に従って製造される:
ステップA:
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−Ν,Ν−ジメチル−アセトアミド(実施例1−1を参照されたい)の遊離塩基(107.5mg;0.34mmol)を乾燥THF(10mL)中に溶解する。この溶液にホルムアルデヒド(36.5%水溶液,52.1μl;0.69mmol)、酢酸(2.5mL)及びMP−CNBH3(2.3mmol/g;325mg;0.75mmol)を順次添加する。1時間撹拌した後、反応が完了する。更に1.5時間撹拌した後、反応混合物を蒸発させる。粗な残渣をシリカゲルで溶離液としてDCM/MeOH(99.5/0.5)を用いるフラッシュクロマトグラフィーにかける。73.1mg(65%)の薄黄色流体2−{[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチル]−メチルアミノ}−Ν,Ν−ジメチル−アセトアミドを得る。
2−{[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチル]−メチルアミノ}−N,N−ジメチル−アセトアミド(73.1mg)をDCM(3mL)中に含む溶液を撹拌し、pH2に達するまで数滴のジオキサン中4M HClを添加する。反応混合物を5分間撹拌した後、蒸発させる、白色固体残渣をEt2O中に懸濁し、2回蒸発させて、77.4mg(96%)の白色固体2−{[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチル]−メチルアミノ}−Ν,Ν−ジメチル−アセトアミド塩酸塩(実施例3−1)を得る。
MW:386.49
質量電荷比:387.28(MH+,ESI pos,3.2KV,25V,400℃)
1H−NMR(300MHz,DMSO−d6+TFA)δ ppm 7.38−7.50(m,1H),7.08−7.17(m,3H),3.98−4.11(m,4H),3.85(t,2H),3.33(t,2H),3.21(s,3H),3.12−3.20(m,2H),2.88(s,3H),2.86(s,3H),1.78−1.91(m,2H),1.65−1.78(m,2H),1.36−1.54(m,2H),0.94(t,3H)。
MW:372.46
質量電荷比:373.30(MH+,ESI pos,3.2KV,25V,400℃)
1H−NMR(300MHz,DMSO−d6+TFA)δ ppm 7.38(t,1H),6.95−7.11(m,3H),4.01(t,2H),3.50(s,2H),3.42(t,2H),3.28(t,2H),2.85(s,3H),2.79(s,3H),2.76(s,3H),1.63−1.79(m,2H),1.35−1.52(m,2H),0.94(t,3H)。
MW:296.39
質量電荷比:297.04(MH+,ESI pos,3.2KV,25V,350℃)
1H−NMR(300MHz,DMSO−d6)δ ppm 9.35(bs,2H),7.22−7.487(m,1H),6.83−7.07(m,3H),5.97(ddd,1H),4.10(s,2H),4.004(t,2H),3.55(td,1H),3.33−3.47(m,1H),2.95(s,3H),2.91(s,3H),1.56−1.78(m,2H),1.29−1.54(m,2H),0.94(t,3H)。
2−(3−メトキシフェニル)アセトニトリル(2g;13.59mmol)を乾燥ジクロロメタン(DCM)(13mL)中に含む0℃に冷却された溶液に不活性雰囲気下で、DCM中BBr3の1M溶液(28.54mmol;28.54mL)をゆっくり1滴ずつ添加する。混合物を室温で20時間撹拌する。次いで、反応混合物を氷に注ぎ、水を添加し、有機相をジクロロメタンで3回抽出し、ブラインで洗浄し、無水Na2SO4で乾燥する。蒸発後、粗な混合物をシリカゲルで溶離液として石油エーテル/EtAc(80/20)を用いるフラッシュクロマトグラフィーにより精製して、1.28g(71%)の2−(3−ヒドロキシフェニル)アセトニトリルを得る。
2−(3−ヒドロキシフェニル)アセトニトリル(2.29g;17.11mmol)を乾燥DMF(25mL)中に含む溶液にK2CO3(7.08g;51.33mmol)、KI(0.61g;3.70mmol)及び1−ブロモブタン(4.69g;3.69mL;34.22mmol)を添加し、混合物を60℃で5時間、次いで室温で一晩撹拌する。TLC(DCM/EtAc 95/5)は出発物質の不在を示している。蒸発後、反応混合物を酢酸エチル(150mL)で抽出し、ブライン(150mL×2)で洗浄する。水性相を0.1N HClで酸性化し、酢酸エチルで再び抽出する。合わせた有機層を無水Na2SO4で乾燥し、濾過し、蒸発させる。粗な混合物をフラッシュクロマトグラフィー(溶離液:石油エーテル/酢酸エチル 99/1)により精製し、蒸発後3.07g(95%)の2−(3−ブトキシフェニル)アセトニトリルを薄黄色油状物として得た。
2−(3−ブトキシフェニル)アセトニトリル(371mg;1.96mmol)をTHF(16mL)中に含む溶液に窒素雰囲気下で−78℃でtert−ブチルリチウム(1268uL;2.16mmol)を1滴ずつ添加する。明黄色溶液は橙色に変わり、撹拌を1時間継続する。N−フルオロベンゼンスルホンイミド(618mg;1.96mmol)をTHF(2mL)中に含む溶液を1滴ずつ添加し、反応物を−78℃で2時間撹拌する。TLC(石油エーテル/EtAc 9:1)は出発物質の不在及び2つのより無極のスポットを示している。次いで、0.01N HClを添加することにより反応物をクエンチした後、更に水を添加し、DCMで抽出する(3回)。合わせた有機層をNa2SO4で乾燥し、濾過し、蒸発させる。粗な残渣をフラッシュクロマトグラフィー(石油エーテル/EtAc、99/1)により精製して、217mg(53%)の2−(3−ブトキシフェニル)−2−フルオロアセトニトリルを無色油状物として得る。
2−(3−ブトキシフェニル)−2−フルオロアセトニトリル(109mg:0.53mmol)を乾燥THF(5mL)中に含む溶液にボランテトラヒドロフラン複合体(2.10mL;2.10mmol)を添加し、反応物を0℃で2時間、次いで室温で6時間撹拌する。LC/MSはほぼ完全変換を示している。数滴のEtOH及び数滴の濃HCl/EtOH(1:5)をゆっくり添加することにより反応物をクエンチし、撹拌を5分間継続する。次いで、DCM及び5% 水性NaHCO3を順次添加した。2相を分離し、水性相をDCMで2回抽出する。合わせた有機層をNa2SO4で乾燥し、濾過し、蒸発させる。粗な残渣をSCXカートリッジ(溶離液:DCM/MeOH 1/1からMeOH/濃水性NH3 95/5)を用いて精製して、2−(3−ブトキシフェニル)−2−フルオロエタンアミン(92mg;0.43mmol;83%)を薄黄色油状物として得る。
2−(3−ブトキシフェニル)−2−フルオロエタンアミン(92mg;0.43mmol)及びBoc2O(0.121mL;0.52mmol)を乾燥THF(6mL)中に含む溶液にDIPEA(0.106mL;0.61mmol)を添加し、反応物を室温で2時間撹拌する。LC/MSは完全変換を示している。DCMを添加し、溶液を5% 水性NaHCO3及び1N HClで洗浄し、無水Na2SO4で乾燥し、濾過し、蒸発させて、tert−ブチル2−(3−ブトキシフェニル)−2−フルオロエチルカルバメート(136mg;0.437mmol;100%)を薄黄色油状物として得る。
tert−ブチル2−(3−ブトキシフェニル)−2−フルオロエチルカルバメート(136mg;0.44mmol)を乾燥DMF(4mL)中に含む溶液を窒素雰囲気下で0℃に冷却し、水素化ナトリウム(22.7mg;0.57mmol)を添加する。混合物を室温で10分間撹拌した後、再び0℃に冷却し、2−クロロ−N,N−ジメチル−アセトアミド(0.054mL;0.524mmol)を添加する。反応混合物を室温で4時間撹拌する。LC/MSは非常に低い変換を示している。追加の水素化ナトリウム(38mg;0.96mmol)を添加し、10分後2−クロロ−N,N−ジメチル−アセトアミド(0.09mL;0.87mmol)を添加する。撹拌を12時間継続する。LC/MSはほぼ完全変換を示している。溶媒を蒸発させ、EtAcを添加し、溶液をブラインで洗浄した後、無水Na2SO4で乾燥し、濾過し、蒸発させる。粗な残渣をフラッシュクロマトグラフィー(DCM/EtAc 96/4から95/5)により精製して、tert−ブチルN−[2−(3−ブトキシフェニル)−2−フルオロエチル]−N−[(2−ジメチルアミノ)−2−オキソエチル)]−カルバメート(100mg;0.25mmol;58%)を無色油状物として得る。
tert−ブチルN−[2−(3−ブトキシフェニル)−2−フルオロエチル]−N−[(2−ジメチルアミノ)−2−オキソエチル)]−カルバメート(96mg;0.24mmol)及びジオキサン中4M HCl(363uL;1.45mmol)を乾燥DCM(6mL)中に含む混合物を室温で4時間撹拌する。LC/MSは完全変換を示している。溶媒を蒸発させて、2−[2−(3−ブトキシフェニル)−2−フルオロエチルアミノ)]−N,N−ジメチル−アセトアミド(50mg;0.17mmol;70%)を薄黄色非晶質固体として得る。これをEtAcと摩砕し、濾過し、乾燥して、22.2mg(0.067mmol;44%)の白色固体2−[2−(3−ブトキシフェニル)−2−フルオロエチルアミノ]−N,N−ジメチル−アセトアミド塩酸塩(実施例4−1)を得た。
これらの化合物をスキーム4に記載されている手順に従って製造した:
実施例4−2:2−{2−フルオロ−2−[3−(3−クロロベンジルオキシ)−フェニル]−エチルアミノ}−N,N−ジメチル−アセトアミド塩酸塩;
実施例4−3:2−{2−フルオロ−2−[3−(3−フルオロベンジルオキシ)−フェニル]−エチルアミノ}−N,N−ジメチル−アセトアミド塩酸塩。
IMR32ヒト神経芽細胞腫細胞はL型及びN型チャネルの両方を構成的に発現する。分化条件下で、IMR32細胞は膜表面上でN型カルシウムチャネルを優先的に発現する。残りのL型カルシウムチャネルは選択的L型ブロッカーのニフェジピンを用いて遮断される。これらの実験条件では、N型チャネルのみが検出され得る。
ND7/23ラット後根神経節由来細胞株はTTXsナトリウムチャネルの混合集団(例えば、Nav1.3、Nav1.2、Nav1.1、Nav1.6)を内生的に発現する。これらの細胞はそれぞれの転写物が存在しないことから分かるようにTTXrナトリウムチャネルを欠いている。ND7/23細胞を10% ウシ胎児血清(FBS,Invitrogen,米国カリフォルニア州)及び1mM ピルビン酸ナトリウムを補充したダルベッコ変法イーグル培地(DMEM,Invitrogen,米国カリフォルニア州)において増殖させる。細胞をポリ−L−リシン被覆プレートに50,000細胞/ウェルで接種し、更に18〜24時間インキュベートした後使用する。
細胞及び方法:N型Ca電流の機能的阻害を、hα1B(hCav2.2)+β1b+α2δ−1サブユニットの一過性トランスフェクション後得た組換えヒトN型チャネルを発現するHEK293細胞に対して全細胞パッチクランプ方法(Hamill O.P.,Marty A.,Neher E.,Sakmann B.,Sigworth F.J.,Pflugers Arch. 391:85−100(1981))を用いて研究した。
遮断の電圧依存性を調べるために2ステッププロトコルを使用する:
N型電流をそれぞれ−110mV(静止状態)または〜−50/−55mV(最大定常不活性化状態の半量)の5000msプレコンディショニング電位から+10mV(試験パルス)に600msステップパルスにより活性化する。
細胞及び方法:ナトリウム電流の機能的阻害を、電位依存性ナトリウムチャネルの混合集団を発現するハイブリッド細胞株ND7/23(Wood JN,Bevan SJ,Coote PR,Dunn PM,Harmar A,Hogan P,Latchman DS,Morrison C,Rougon G,Theveniau M.:“Novel cell lines display properties of nociceptive sensory neurons”,Proc.Biol.Sci. Sep 22;241(1302):187−94(1990))に対して全細胞パッチクランプ方法(Hamill O.P.,Marty A.,Neher E.,Sakmann B.,Sigworth F.J.,Pflugers Arch. 391:85−100(1981))を用いて研究する。
ナトリウム電流をそれぞれ−100mV(静止状態)または−70mV(最大定常不活性化状態の半量)の2000msプレコンディショニング電位から0mV(試験パルス)に30msステップパルスにより活性化する。
細胞作成及び培養:皮質ニューロンは未発達のWistarラット(E17−E19)から作成する。E17/19ラットの脳を取り出し、氷冷ハンクス溶液(ハンクス溶液(Invitrogen,米国カリフォルニア州)+グルコース 30%+Pen−Strep 100×(Invitrogen,米国カリフォルニア州)100U−100μg/ml及びHepes−NaOH 5mM)中に入れる。
バキュロウィルス感染した昆虫細胞由来のミクロソームであるスーパーソームを用いるインビトロ阻害研究を実施することによりシトクロムP4502D6(CYP2D6)の阻害を評価する。バキュロウィルスは酵素cDNAを代謝する1つ以上の薬物を発現するように工学処理されている。スーパーソームはヒト肝臓ミクロソーム酵素と同一の酵素反応を触媒するが、他のミクロソーム源よりも非常に高い酵素活性を含有している(Crespi C.L. and Penman B.W.,Advances Pharmacology,43,171−188(1997);Crespi C.L. and Miller V.P.,Analytical Biochemistry,248,188−190(1997))。
試験化合物をIC50アッセイにおいて所望される最高最終濃度の500×でDMSO中に溶解させる。30mの脱イオン水を37℃に予め加温し、すべてのキット成分を氷上に置く。カラム1の各ウェルに対して、149.4μLのNADPH−コファクターミックス(187.5μLのコファクター、150μLのG6PDH、100μLの対照タンパク質及び14.56mLの37℃の水)を添加する。
プレインキュベーション(10’)後、カラム1〜10の各ウェルに100μLの酵素/基質ミックスを添加する。プレートを37℃で30分間インキュベートする。この後、各ウェルに対して75μLの停止試薬を添加する。ブランク対照については、カラム11及び12に酵素/基質ミックスを添加する。
プレートを390nmの励起波長及び460nmの発光波長でVictorプレートリーダー(Perkin Elmer,米国マサチューセッツ州)で測定する。
ラット(体重200g)においてパラフィン油と乳化剤のモノオレイン酸マンニドの混合物中に熱殺菌し、乾燥させた結核菌(Mycobacterium tubercolosis)を含有している完全フロイントアジュバント(CFA)の100μlを左後肢に足底内注射することにより単関節炎を誘発させる。CFA注射により、注射から数時間後から限局性浮腫及び炎症の部分が生じ、機械的引込み閾値は段階的減少する。
機械的異痛閾値をChaplanら(Chaplan S.R.,Bach F.W.,Pogrel J.W.,Chung J.M.,Yaksh T.L.,J.Neurosci.Methods 53:55−63(1994))の方法に従って測定する。ラットを24×10×15cmの個別のプラスチックボックス中の金網床上に載せ、試験前約30分間順化させる。[10×力(mg)]のLog10で表示して2.83から5.88の範囲で対数的に漸増する剛性を有する一連の校正フォンフレイヘア(Stoelting,米国イリノイ州ウッドデール)を修正アップ・ダウン方法(Dixon W.,J.Am.Stat.Assoc. 60:967−978(1965))で肢に適用する。最初に選択したヘアに対する肢引込み応答の不在下で、機敏な引込みが記録されるまでより強い刺激に対応するより太いヘアを刺す。手順を2回繰り返す。各ヘアを僅かな曲げを起こすのに十分な力で肢に対して垂直に刺し、2〜3秒保持する。同一強度の刺激を数秒間隔で後肢に5/6回加える。機械的閾値を動物が反応する(肢の引込み、殴る、または振とう)フォンフレイヘアの力を示す[10×力(mg)]のLog10として表示する。
神経障害性疼痛に対する効果をラットの慢性絞扼傷モデルにおいて試験する(Bennett,G.J. and Xie,Y.K.,“A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man”,Pain,33,87−107(1988))。ペントバルビタール麻酔(ネンブタール,50mg/kg,i.p.)下で、雄Sprague−Dawleyラット(140〜160g)の右総座骨神経に片側複数結紮を実施する。座骨神経を中大腿部のレベルでの鈍的切開により露出させ、神経弓上循環を妨げないように注意を払いながら4本の緩い結紮糸(5−0クローミック腸線)を神経の周りに配置する。手術後、動物を1週間回復させる。動物は少なくとも5週間安定である冷感異痛を生ずる。冷感異痛を水浴により4℃の一定温度まで冷却した金属プレートを用いて試験する。各用量及びビヒクルについて10のグループに無作為に割り当てた動物を試験化合物の適用の前後2分間観察し、活発な引込み反応の数をカウントする。適用から幾つかの時点を試験する。各時点の可能な最大効果%(%MPE)及び平均の標準誤差(SEM)を100%MPEとして使用した予備試験値で調べる。データ下面積(AUD)を観察期間毎に計算し、ビヒクル対照の阻害パーセントとして表示する。有意差はパーセントAUD値に対する対応t検定により計算する。
最大電気ショック(MES)試験は齧歯類モデルにおいて抗てんかん薬をスクリーニングする際に通常使用されている。
このモデルでは、マウスをd−アンフェタミンと不安解消量のベンゾジアゼピンのクロロジアゼポキシドの混合物で処置する(Rushton R.,Steinberg H.,“Combined effects of chlordiazepoxide and d−amphetamine on activity of rats in an unfamiliar environment”,Nature 211:1312−3(1966);Arban R.,Maraia G.,Brackenborough K.,Winyard L.,Wilson A.,Gerrard P.,Large C.,“Evaluation of the effects of lamotrigine,valproate and carbamazepine in a rodent model of mania”,Behavioural Brain Research,158:123−132(2005))。このモデルは双極性障害中の躁病の幾つかの状態に似せるように要求されている。重要なことは、d−アンフェタミンとクロロジアゼポキシドの混合物により誘発される活動過多は認められている気分安定薬のリチウム及び他の気分安定薬(例えばバルプロ酸マグネシウム及びカルバマゼピン)を予め投与することにより予防され得る。従って、このモデルは双極性障害のモデルとしての面及び予測妥当性を有しており、試験化合物が可能性ある気分安定薬候補者であり得るかを調べるための貴重なツールに相当する。
認知障害は多くの場合統合失調症と関連しており、患者の回復及び社会への再統合に向けられる障害のコアエレメントとして認識されるようになった。
動物:雄DBA/2Nマウス(Charles River,イタリー)を使用する。マウスの体重は実験開始時25〜30gであり、恒温条件(21℃)、12時間の明−12時間の暗サイクル(午前7:00〜午後7:00電灯を点灯させる)で収容する。餌(Rieper,イタリー)は自由に摂取することができる。動物は試験の日々の終わりに2時間水を摂取できる。
マウスを1週間ならし、体重を記録する。その後、体重が安定するまで(8日間)夕方水に2時間しか摂取させないことにより摂水妨害する。次いで、次の2日間にわたりマウスを自分のケージにおいてオペラント手順においてその後使用する強化子(10% スクロース溶液)に慣らす。その後2日、マウスをオペラントボックスに慣らす。この段階で、10% スクロース溶液はボックスのレセプタクルホールの下に置かれている小さいボールに入れられている。最初、マウスは5秒毎に液体ご褒美がレセプタクルホール中の小さなカップで利用可能であることを学習しなげればならない。この間、頭部入口を記録する。次の期間中、マウスは照明付きホールに鼻を突っ込むように訓練される。水レセプタクルに鼻を突っ込んだ直後に、ホールの1つの背後のLEDが点灯する。点灯しているホール中に鼻を突っ込むと光刺激が消え、液体ディッパーはレセプタクルホール中に0.01mLの液体ご褒美を与える。他の4つのホールの1つにおける応答は結果を持たず、記録されない。光刺激を順序不同で5つのすべてのホールで与える。1回30分のセッションで少なくとも50回のご褒美つきノーズポーキングトライアルが完了した後、マウスは5−CSRT課題に切り換える。
薬物嗜癖は強迫感にとらわれて薬物を探し、摂取することを特徴とする病理学的行動である。これらの行動変化の1つの動物モデルは、薬物誘発性行動感作として公知の齧歯類に精神刺激薬を繰り返し投与することにより誘発される歩行活動の長く続く増加である(Robinson T.E. and Berridge K.C.,Brain Res.Brain Res.Rev.,18,247−91(1993))。試験化合物の効果はラットのコカイン誘発性行動感作のモデルにおいて評価する。
実験は麻酔下の成体雌Sprague Dawleyラット(170〜200g)を用いて実施する。カテーテル(PE−50)を腹部正中切開して膀胱頂部を介して膀胱に挿入した後、0.15% 酢酸の連続注入中膀胱活動をモニターするために膀胱内圧を測定する。酢酸の連続膀胱内注入は膀胱を刺激し、麻酔下のラットの収縮間隔(ICI)を短縮する。本発明の化合物で処置されたラットにおいて酢酸を膀胱内注入の前後にICI、最大収縮圧、及び膀胱の収縮反射を含めた圧力閾値を測定する。
実験は目が覚めている及び麻酔下の成体雌Sprague Dawleyラット(170〜200g)を用いて実施する。化学物質性膀胱炎をCYPにより誘発し、CYPは刺激物のアクロレインに代謝され、尿中に排泄される。CYP(150mg/kg/i.p.)を実験の前日に投与する。CYPでの前処置は膀胱の刺激及び排尿の間約150〜200秒のICIで非常に頻繁の排尿を引き起こす。
動物及び手術:雄Wistarラット(250〜350g)に食塩水中に溶解させたペントバルビタールナトリウム(50mg/kg i.p.)を用いて麻酔をかける。
の化合物を、塩基の存在下で化合物R1−Z(ここで、R1は水素を除いて上に記載されている意味を有し、Zはハロゲン原子または良好な離脱基、例えばメタンスルホニルオキシ、p−トルエンスルホニルオキシまたはトリフルオロメタンスルホニルオキシである)と反応させること、または還元剤の存在下で式R7R8CO(ここで、R7及びR8は両方水素を表し、または隣接カルボニル基と一緒に場合によりヒドロキシル基または(C1−C4)アルコキシ基で置換されている(C2−C4)脂肪族アルデヒドまたは(C3−C4)脂肪族ケトンを表し、或いはR7及びR8は隣接カルボニル基と一緒に(C3−C8)脂環式ケトンを表す)のカルボニル化合物と反応させることにより製造され得る。
Claims (27)
- 場合により単離された形態の単一光学異性体としてまたは任意の比率のその混合物としての、一般式I
Wは基A−[(CH2)m−O]−であり、ここでmは0、1、2または3であり、Aは場合により1から3個のフッ素原子で置換されている(C1−C4)アルキル;(C3−C6)シクロアルキル;場合によりハロ、メチル、メトキシ、トリフルオロメチル、アセチルアミノ及びジメチルアミノメチルから選択される基で置換されているフェニル;場合によりクロロ基で置換されているチエニル;フラニル;イソオキサゾリル;チアゾリル;ピペリジニル;モルホリニル;ピリジニルまたはピリミジニルであり、前記したピリジニル及びピリミジニル環は場合により1または2個のメトキシ基で置換されており、
Jは独立して水素、(C1−C4)アルキル、(C1−C4)アルコキシまたはハロ基であり、
nは1または2であり、
R1は水素;場合によりヒドロキシ基または(C1−C4)アルコキシ基で置換されている(C1−C4)アルキル;または(C3−C8)シクロアルキルであり、
R2及びR2’は独立して水素;場合により(C1−C4)アルコキシ基で置換されている(C1−C4)アルキル;場合により(C1−C4)アルキル、(C1−C4)アルコキシまたはハロ基で置換されているフェニル;場合によりベンゼン環上で(C1−C4)アルキル、(C1−C4)アルコキシまたはハロ基で置換されているベンジルであり、或いは
R2及びR2’は隣接炭素原子と一緒に(C3−C6)シクロアルキリデン基を形成し、
R3は水素または(C1−C4)アルキルであり、
R4は水素、(C1−C4)アルキル、フェニル、シクロヘキシルまたはベンジルであり、或いは
R3及びR4は隣接窒素原子と一緒にアゼチジニル、ピロリジニル、モルホリニル、ピペリジニルまたはピペラジニル環、前記ピペリジニル環は場合により1または2個の(C1−C2)アルキル基で置換されており、並びに前記ピペラジニル環は場合により他のN原子上で(C1−C4)アルキル、ベンジルまたはフェニルスルホニル基で置換されている;またはベンゼン環と縮合したピロリジニル、ピペリジニル、モルホリニルまたはピペラジニル環を形成し、
R5は水素またはフルオロであり、並びに
R6はフルオロである)
の化合物及びその医薬的に許容され得る塩。 - Wは基A−[(CH2)m−O]−であり、ここでmは0、1、2または3であり、Aは場合により1から3個のフッ素原子で置換されている(C1−C4)アルキル;(C3−C6)シクロアルキル;場合によりハロ基で置換されているフェニル;またはチアゾリルであり、
Jは独立して水素、C1−C4アルキル、クロロまたはフルオロであり、
nは1または2であり、
R1は水素;場合によりヒドロキシ基または(C1−C4)アルコキシ基で置換されている(C1−C4)アルキル;または(C3−C6)シクロアルキルであり、
R2は水素または(C1−C4)アルキルであり、
R2’は水素または場合により(C1−C4)アルコキシで置換されている(C1−C4)アルキルまたはフェニル基であり、前記フェニル基は場合により(C1−C4)アルコキシ基で置換されており、
R3は水素または(C1−C4)アルキルであり、
R4は水素、(C1−C4)アルキル、フェニルまたはシクロヘキシルであり、或いは
R3及びR4は隣接窒素原子と一緒にアゼチジニル、ピロリジニル、モルホリニル、ピペリジニルまたはピペラジニル、前記ピペリジニル環は場合により1または2個の(C1−C2)アルキル基で置換されており、並びに前記ピペラジニル環は場合により他のN原子上で(C1−C4)アルキル、ベンジルまたはフェニルスルホニル基で置換されている;またはベンゼン環と縮合したピロリジニル、ピペリジニル、モルホリニルまたはピペラジニル環を形成し、
R5は水素またはフルオロであり、並びに
R6はフルオロである;
場合により単離された形態の単一光学異性体としてまたは任意の比率のその混合物としての、請求項1に記載の化合物及びその医薬的に許容され得る塩。 - Wは基A−[(CH2)m−O]−であり、ここでmは1または2であり、Aは場合により1から3個のフッ素原子で置換されている(C1−C4)アルキル;場合によりクロロまたはフルオロ基で置換されているフェニル;またはチアゾリルであり、
Jは独立して水素、メチルまたはフルオロであり、
nは1〜2であり、
R1は水素;場合によりヒドロキシ基または(C1−C4)アルコキシ基で置換されている(C1−C4)アルキルであり、
R2は水素またはメチルであり、
R2’は水素;または場合によりメトキシで置換されている(C1−C4)アルキルまたはフェニル基であり、前記フェニル基は場合によりメトキシ基で置換されており、
R3は水素または(C1−C4)アルキルであり、
R4は水素、(C1−C4)アルキル、フェニル、またはシクロヘキシルであり、或いは
R3及びR4は隣接窒素原子と一緒にアゼチジニル、ピロリジニル、モルホリニル、ピペリジニルまたはピペラジニル環、前記ピペリジニル環は場合により1または2個のメチル基で置換されており、並びに前記ピペラジニル環は場合により他のN原子上でメチル、ベンジルまたはフェニルスルホニル基で置換されている;またはベンゼン環と縮合したピロリジニル、ピペリジニル、モルホリニルまたはピペラジニル環を形成し、
R5は水素またはフルオロであり、並びに
R6はフルオロである
場合により単離された形態の単一光学異性体としてまたは任意の比率のその混合物としての、請求項1及び2のいずれか1項に記載の化合物及びその医薬的に許容され得る塩。 - 2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−N,N−ジメチル−アセトアミド、
2−[2,2−ジフルオロ−2−(3−ペンチルオキシフェニル)−エチルアミノ]−N,N−ジメチル−アセトアミド、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−N,N−ジプロピル−アセトアミド、
2−[2,2−ジフルオロ−2−(3−ブトキシ−4−メチルフェニル)−エチルアミノ]−N,N−ジメチル−アセトアミド、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−N,N−ジブチル−アセトアミド、
2−[2,2−ジフルオロ−2−(3−ヘキシルオキシフェニル)−エチルアミノ]−N,N−ジメチル−アセトアミド、
2−{2,2−ジフルオロ−2−[3−(4,4,4−トリフルオロブトキシ)−フェニル]−エチルアミノ}−N,N−ジメチル−アセトアミド、
2−[2,2−ジフルオロ−2−(3−ペンチルオキシフェニル)−エチルアミノ]−N,N−ジプロピル−アセトアミド、
2−{2,2−ジフルオロ−2−[3−(3−(3−フルオロフェニル)−プロポキシ)−フェニル]−エチルアミノ}−N,N−ジメチル−アセトアミド、
2−{2,2−ジフルオロ−2−[3−(3−(3−クロロフェニル)−プロポキシ)−フェニル]−エチルアミノ}−N,N−ジメチル−アセトアミド、
2−[2,2−ジフルオロ−2−(3−ブトキシ−2−フルオロフェニル)−エチルアミノ]−N,N−ジメチル−アセトアミド、
2−{2,2−ジフルオロ−2−[3−(3−フェニルプロポキシ)−フェニル]−エチルアミノ}−N,N−ジメチル−アセトアミド、
2−{2,2−ジフルオロ−2−[3−(3−チアゾル−2−イル−プロポキシ)−フェニル]−エチルアミノ}−N,N−ジメチル−アセトアミド、
2−[2,2−ジフルオロ−2−(3−ベンジルオキシフェニル)−エチルアミノ]−N,N−ジメチル−アセトアミド、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−1−(ピロリジン−1−イル)−エタノン、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−N−メチル−N−フェニル−アセトアミド、
2−{2,2−ジフルオロ−2−[3−(3−フェニルプロポキシ)−フェニル]−エチルアミノ}−1−(ピロリジン−1−イル)−エタノン、
2−{2,2−ジフルオロ−2−[3−(4,4,4−トリフルオロブトキシ)−フェニル]−エチルアミノ}−1−(ピロリジン−1−イル)−エタノン、
2−[2,2−ジフルオロ−2−(3−ベンジルオキシフェニル)−エチルアミノ]−1−(モルホリン−4−イル)−エタノン、
2−{2,2−ジフルオロ−2−[3−(3−フェニルプロポキシ)−フェニル]−エチルアミノ}−1−(モルホリン−4−イル)−エタノン、
2−{2,2−ジフルオロ−2−[3−(4,4,4−トリフルオロブトキシ)−フェニル]−エチルアミノ}−1−(モルホリン−4−イル)−エタノン、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−1−(2H−ベンゾ[b][1,4]オキサジン−4(3H)−イル)−エタノン、
.2−[2,2−ジフルオロ−2−(3−ベンジルオキシフェニル)−エチルアミノ]−1−(ピロリジン−1−イル)−エタノン、
2−{2,2−ジフルオロ−2−[3−(3−フェニルプロポキシ)−フェニル]−エチルアミノ}−N−メチル−N−フェニル−アセトアミド、
2−{2,2−ジフルオロ−2−[3−(4,4,4−トリフルオロブトキシ)−フェニル]−エチルアミノ}−N−メチル−N−フェニル−アセトアミド、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−1−(4−メチルピペラジン−1−イル)−エタノン、
2−{2,2−ジフルオロ−2−[3−(3−フェニルプロポキシ)−フェニル]−エチルアミノ}−1−(4−メチルピペラジン−1−イル)−エタノン、
2−{2,2−ジフルオロ−2−[3−(4,4,4−トリフルオロブトキシ)−フェニル]−エチルアミノ}−1−(4−メチルピペラジン−1−イル)−エタノン、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−1−(ピペリジン−1−イル)−エタノン、
2−{2,2−ジフルオロ−2−[3−(3−フェニルプロポキシ)−フェニル]−エチルアミノ}−1−(ピペリジン−1−イル)−エタノン、
2−{2,2−ジフルオロ−2−[3−(4,4,4−トリフルオロブトキシ)−フェニル]−エチルアミノ}−1−(ピペリジン−1−イル)−エタノン、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−N,N−ジエチル−アセトアミド、
2−{2,2−ジフルオロ−2−[3−(2−フルオロベンジルオキシ)−フェニル]−エチルアミノ}−N,N−ジメチル−アセトアミド、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−1−(シス−3,5−ジメチルピペリジン−1−イル)−エタノン、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−1−(3,4−ジヒドロイソキノリン−2(1H)−イル)−エタノン、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−N,N−ジイソプロピル−アセトアミド、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−N−シクロヘキシル−N−メチル−アセトアミド、
2−[2,2−ジフルオロ−2−(3−ベンジルオキシフェニル)−エチルアミノ]−1−(ピペリジン−1−イル)−エタノン、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−1−[4−(フェニルスルホニル)−ピペラジン−1−イル]−エタノン、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−1−(インドリン−1−イル)−エタノン、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−1−(4−ベンジルピペラジン−1−イル)−エタノン、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−1−(アゼチジン−1−イル)−エタノン、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−N,N−ジメチル−プロパンアミド、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−3−メトキシ−N,N−ジメチル−プロパンアミド、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−3−(4−メトキシフェニル)−N,N−ジメチル−プロパンアミド、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−2−N,N−トリメチル−プロパンアミド、
2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−4−N,N−トリメチル−ペンタンアミド、
2−{[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチル]−メチルアミノ}−N,N−ジメチル−アセトアミド、
2−{[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチル]−(3−メトキシプロピル)−アミノ}−N,N−ジメチル−アセトアミド、
2−{[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチル]−(2−メトキシエチル)−アミノ}−N,N−ジメチル−アセトアミド、
2−[2−フルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−N,N−ジメチル−アセトアミド、
2−{2−フルオロ−2−[3−(3−クロロベンジルオキシ)−フェニル]−エチルアミノ}−N,N−ジメチル−アセトアミド、
2−{2−フルオロ−2−[3−(3−フルオロベンジルオキシ)−フェニル]−エチルアミノ}−N,N−ジメチル−アセトアミド
から選択される、場合により単離された形態の単一光学異性体としてまたは任意の比率のその混合物としての、請求項1から3のいずれか1項に記載の化合物、及びその医薬的に許容され得る塩。 - 2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−N,N−ジメチル−アセトアミド、2−[2−フルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−N,N−ジメチル−アセトアミド、単離された形態のその単一光学異性体または任意の比率のその混合物から選択される請求項4に記載の化合物、及びその医薬的に許容され得る塩。
- 2−[2,2−ジフルオロ−2−(3−ブトキシフェニル)−エチルアミノ]−N,N−ジメチル−アセトアミドである請求項5に記載の化合物。
- 医薬的に許容され得る塩は塩酸塩である請求項1から6のいずれか1項に記載の化合物。
- 薬剤として使用するための請求項1から7のいずれか1項に記載の化合物。
- 電位依存性ナトリウム及び/またはカルシウムチャネルの機能不全に起因する障害に対するナトリウム及び/またはカルシウムチャネルモジュレーターとして活性な薬剤として使用するための請求項1から8のいずれか1項に記載の化合物。
- 前記の電位依存性ナトリウム及び/またはカルシウムチャネルの機能不全に起因する障害は神経障害性疼痛、慢性疼痛、急性疼痛、頭痛、神経状態、神経変性障害、認知障害、精神障害、眩暈、耳鳴り、筋痙攣、心血管疾患、内因性物質の過剰分泌、分泌過多または他の不適切な細胞分泌を伴う内分泌障害、肝疾患、全身に影響を及ぼす炎症プロセス、胃腸(GI)管の障害、尿生殖器の障害、眼科疾患及び摂食障害から選択される請求項9に記載の化合物。
- 神経障害性疼痛、慢性疼痛及び/または急性疼痛の治療用薬剤として使用するための請求項1から10のいずれか1項に記載の化合物。
- 頭痛のような神経障害の治療用薬剤として使用するための請求項1から10のいずれか1項に記載の化合物。
- てんかんのような神経状態の治療用薬剤として使用するための請求項1から10のいずれか1項に記載の化合物。
- 認知及び/または精神障害の治療用薬剤として使用するための請求項1から10のいずれか1項に記載の化合物。
- 電位依存性ナトリウム及び/またはカルシウムチャネルの機能不全に起因する全身に影響を及ぼす炎症プロセス、胃腸管の障害、尿生殖器の障害、眼科疾患、肝疾患、心血管及び/または神経変性障害の治療用薬剤として使用するための請求項1から10のいずれか1項に記載の化合物。
- 低代謝者である、すなわちCYP2D6機能を殆どまたは全く持たない、或いはCYP2D6阻害剤である薬物を服用している患者における請求項9から15のいずれか1項に記載の電位依存性ナトリウム及び/またはカルシウムチャネルの機能不全に起因する障害の治療用薬剤として使用するための請求項1から7のいずれか1項に記載の化合物。
- 1つ以上の他の治療薬と共に薬剤として使用するための請求項1から16のいずれか1項に記載の化合物。
- 活性成分としての請求項1から7のいずれか1項に記載の化合物を医薬的に許容され得る賦形剤と一緒に含有している医薬組成物。
- 追加の治療薬を含有している請求項18に記載の医薬組成物。
- 治療を要する患者に対してナトリウム及び/またはカルシウムチャネル調節有効量の請求項1から7のいずれか1項に記載の化合物を投与することを含む、前記患者における電位依存性ナトリウム及び/またはカルシウムチャネルの機能不全に起因する障害の治療方法。
- 電位依存性ナトリウム及び/またはカルシウムチャネルの機能不全に起因する障害は請求項10に記載されている神経障害性疼痛、慢性疼痛、急性疼痛、頭痛、神経状態、神経変性障害、認知障害、精神障害、眩暈、耳鳴り、筋痙攣、心血管疾患、内因性物質の過剰分泌、分泌過多または他の不適切な細胞分泌を伴う内分泌障害、肝疾患、全身に影響を及ぼす炎症プロセス、胃腸(GI)管の障害、尿生殖器の障害、眼科疾患及び摂食障害から選択される、請求項20に記載の方法。
- 障害は神経障害性疼痛、慢性疼痛及び/または急性疼痛である請求項20及び21のいずれか1項に記載の方法。
- 障害は頭痛である請求項20及び21のいずれか1項に記載の方法。
- 障害は認知及び/または精神障害である請求項20及び21のいずれか1項に記載の方法。
- 障害はてんかんのような神経状態である請求項20及び21のいずれか1項に記載の方法。
- 障害は電位依存性ナトリウム及び/またはカルシウムチャネルの機能不全に起因する全身に影響を及ぼす炎症プロセス、胃腸管の障害、尿生殖器の障害、眼科疾患、肝疾患、心血管及び/または神経変性障害である請求項20及び21のいずれか1項に記載の方法。
- 患者は低代謝者である、すなわちCYP2D6機能を殆どまたは全く持たない、或いはCYP2D6阻害剤である薬物を服用している患者である請求項20から26のいずれか1項に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11171522.3 | 2011-06-27 | ||
EP11171522 | 2011-06-27 | ||
PCT/EP2012/060006 WO2013000651A1 (en) | 2011-06-27 | 2012-05-29 | Fluorinated arylalkylaminocarboxamide derivatives |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2014523888A true JP2014523888A (ja) | 2014-09-18 |
JP2014523888A5 JP2014523888A5 (ja) | 2015-03-12 |
JP6116555B2 JP6116555B2 (ja) | 2017-04-19 |
Family
ID=46210226
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014517549A Active JP6116555B2 (ja) | 2011-06-27 | 2012-05-29 | フッ素化アリールアルキルアミノカルボキサミド誘導体 |
Country Status (27)
Country | Link |
---|---|
US (2) | US9447029B2 (ja) |
EP (1) | EP2723710B1 (ja) |
JP (1) | JP6116555B2 (ja) |
KR (1) | KR101967603B1 (ja) |
CN (1) | CN103781759B (ja) |
AR (1) | AR086743A1 (ja) |
AU (1) | AU2012278193B2 (ja) |
BR (1) | BR112013033389B1 (ja) |
CA (1) | CA2833824C (ja) |
CY (1) | CY1118033T1 (ja) |
DK (1) | DK2723710T3 (ja) |
EA (1) | EA022973B1 (ja) |
ES (1) | ES2602140T3 (ja) |
HK (1) | HK1196604A1 (ja) |
HR (1) | HRP20161412T1 (ja) |
HU (1) | HUE030031T2 (ja) |
IL (1) | IL229762A (ja) |
LT (1) | LT2723710T (ja) |
ME (1) | ME02524B (ja) |
MX (1) | MX345873B (ja) |
PL (1) | PL2723710T3 (ja) |
PT (1) | PT2723710T (ja) |
RS (1) | RS55240B1 (ja) |
SI (1) | SI2723710T1 (ja) |
SM (1) | SMT201600405B (ja) |
TW (1) | TWI541220B (ja) |
WO (1) | WO2013000651A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019532911A (ja) * | 2017-06-20 | 2019-11-14 | ラクオリア創薬株式会社 | Nav1.7およびNav1.8遮断薬としてのアミド誘導体 |
JP2020536941A (ja) * | 2017-10-16 | 2020-12-17 | エステベ ファーマシューティカルズ, ソシエダッド アノニマEsteve Pharmaceuticals, S.A. | 疼痛及び疼痛に関連する状態を治療するためのプロパンアミン誘導体 |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016115054A2 (en) * | 2015-01-13 | 2016-07-21 | Vivreon Biosciences, Llc | Modulators of ca2+ release-activated ca2+ (crac) channels and pharmaceutical uses thereof |
WO2019144805A1 (zh) * | 2018-01-25 | 2019-08-01 | 四川科伦博泰生物医药股份有限公司 | 取代的苯乙胺化合物及其制备方法和用途 |
CN113272293B (zh) * | 2018-11-02 | 2024-06-14 | 默沙东有限责任公司 | 作为nav1.8抑制剂的2-胺基-n-杂芳基-烟酰胺 |
EP3725769A1 (en) | 2019-04-17 | 2020-10-21 | Newron Pharmaceuticals S.p.A. | Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives |
EP3725768A1 (en) | 2019-04-17 | 2020-10-21 | Newron Pharmaceuticals S.p.A. | Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002539193A (ja) * | 1999-03-16 | 2002-11-19 | メルク フロスト カナダ アンド カンパニー | カスパーゼ−3阻害薬としてのγ−ケト酸ジペプチド類 |
JP2009521417A (ja) * | 2005-12-22 | 2009-06-04 | ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー | カルシウム及び/又はナトリウムチャネル調節物質としての2−フェニルエチルアミノ誘導体 |
WO2009128521A1 (ja) * | 2008-04-15 | 2009-10-22 | 帝人ファーマ株式会社 | システインプロテアーゼ阻害剤 |
JP2010529969A (ja) * | 2007-06-15 | 2010-09-02 | ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー | 置換2−[2−(フェニル)エチルアミノ]アルカンアミド誘導体ならびにナトリウムおよび/またはカルシウムチャネル調節剤としてのこれらの使用 |
Family Cites Families (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5051403A (en) | 1989-11-22 | 1991-09-24 | Neurex Corporation | Method of treating ischemia-related neuronal damage |
DE69225499T2 (de) | 1991-12-30 | 1999-02-04 | Neurex Corp | Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie |
GB9500691D0 (en) | 1995-01-13 | 1995-03-08 | Smithkline Beecham Plc | Compounds |
GB9518572D0 (en) | 1995-09-12 | 1995-11-15 | Smithkline Beecham Plc | Compounds |
WO1998054123A1 (en) | 1997-05-30 | 1998-12-03 | Warner-Lambert Company | Substituted peptidylamine calcium channel blockers |
DE19740110A1 (de) | 1997-09-12 | 1999-03-18 | Boehringer Ingelheim Pharma | Substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocin-10-ole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
IT1295423B1 (it) | 1997-10-10 | 1999-05-12 | Medivis S R L | Uso della flunarizina nella terapia topica del glaucoma |
WO1999055688A1 (en) | 1998-04-27 | 1999-11-04 | Warner-Lambert Company | Substituted diarylalkyl amides as calcium channel antagonists |
US6011035A (en) | 1998-06-30 | 2000-01-04 | Neuromed Technologies Inc. | Calcium channel blockers |
AU4329499A (en) | 1998-07-30 | 2000-02-21 | Warner-Lambert Company | Reduced dipeptide analogues as calcium channel antagonists |
WO2001021621A1 (en) | 1999-09-22 | 2001-03-29 | Ortho-Mcneil Pharmaceutical, Inc. | BENZO-FUSED DITHIEPINO[6,5-b]PYRIDINES, AND RELATED COMPOSITIONS AND METHODS |
ATE266666T1 (de) | 2000-03-23 | 2004-05-15 | Ortho Mcneil Pharm Inc | Thiepino(3,2-b)dihydropyridine und relatierte zusammensetzungen und verfahren |
BR0109706A (pt) | 2000-03-31 | 2003-02-04 | Euro Celtique Sa | Aminopiridinas e seus usos como anticonvulsivantes e bloqueadores dos canais de sódio |
US6521647B2 (en) | 2000-04-04 | 2003-02-18 | Pfizer Inc. | Treatment of renal disorders |
SE0102858D0 (sv) | 2001-08-27 | 2001-08-27 | Astrazeneca Ab | N-type calcium channel antagonists for the treatment of pain |
AU2002364545A1 (en) | 2001-12-27 | 2003-07-24 | Ortho-Mcneil Pharmaceutical Inc. | Aroyl pyrrole heteroeryl and methanols useful for treating a central nervous system disorder |
WO2004087125A1 (en) | 2003-04-02 | 2004-10-14 | Ionix Pharmaceuticals Limited | Amino acid derivatives as inhibitors of mammalian sodium channels |
MX2007002410A (es) | 2004-08-30 | 2007-05-07 | Neuromed Pharmaceuticals Ltd | Derivados de urea como bloqueadores de canal de calcio. |
AU2005282761B2 (en) | 2004-09-02 | 2012-02-02 | Vertex Pharmaceuticals Incorporated | Quinazolines useful as modulators of ion channels |
CN101018546B (zh) | 2004-09-10 | 2013-06-12 | 纽朗制药有限公司 | 作为钠和/或钙通道选择性调节剂的(卤代苄氧基)苄氨基-丙酰胺类 |
AR056968A1 (es) | 2005-04-11 | 2007-11-07 | Xenon Pharmaceuticals Inc | Compuestos espiro-oxindol y composiciones farmacéuticas |
WO2007021941A2 (en) | 2005-08-16 | 2007-02-22 | Icagen, Inc. | Inhibitors of voltage-gated sodium channels |
WO2007145922A2 (en) | 2006-06-09 | 2007-12-21 | Merck & Co., Inc. | Benzazepinones as sodium channel blockers |
US20090012010A1 (en) | 2007-05-18 | 2009-01-08 | Neuromed Phramaceuticals Ltd. | Amino acid derivatives as calcium channel blockers |
WO2009005460A1 (en) | 2007-06-29 | 2009-01-08 | Astrazeneca Ab | Small molecule inhibitors of navl.7 sodium channels for the treatment of pain disorders |
US7994174B2 (en) | 2007-09-19 | 2011-08-09 | Vertex Pharmaceuticals Incorporated | Pyridyl sulfonamides as modulators of ion channels |
JP2010540628A (ja) | 2007-10-04 | 2010-12-24 | メルク・シャープ・エンド・ドーム・コーポレイション | カルシウムチャネル遮断薬としてのn−置換されたオキシインドリン誘導体 |
GB0813142D0 (en) | 2008-07-17 | 2008-08-27 | Glaxo Group Ltd | Novel compounds |
JP5421368B2 (ja) | 2008-08-01 | 2014-02-19 | パーデュー、ファーマ、リミテッド、パートナーシップ | テトラヒドロピリジニルおよびジヒドロピロリル化合物およびそれらの使用 |
-
2012
- 2012-05-29 PL PL12726067T patent/PL2723710T3/pl unknown
- 2012-05-29 ME MEP-2016-219A patent/ME02524B/me unknown
- 2012-05-29 WO PCT/EP2012/060006 patent/WO2013000651A1/en active Application Filing
- 2012-05-29 PT PT127260677T patent/PT2723710T/pt unknown
- 2012-05-29 MX MX2013013776A patent/MX345873B/es active IP Right Grant
- 2012-05-29 HU HUE12726067A patent/HUE030031T2/en unknown
- 2012-05-29 RS RS20160838A patent/RS55240B1/sr unknown
- 2012-05-29 SI SI201230731A patent/SI2723710T1/sl unknown
- 2012-05-29 KR KR1020147002151A patent/KR101967603B1/ko active IP Right Grant
- 2012-05-29 EA EA201490166A patent/EA022973B1/ru unknown
- 2012-05-29 CN CN201280029061.XA patent/CN103781759B/zh active Active
- 2012-05-29 AU AU2012278193A patent/AU2012278193B2/en active Active
- 2012-05-29 LT LTEP12726067.7T patent/LT2723710T/lt unknown
- 2012-05-29 BR BR112013033389-8A patent/BR112013033389B1/pt active IP Right Grant
- 2012-05-29 EP EP12726067.7A patent/EP2723710B1/en active Active
- 2012-05-29 DK DK12726067.7T patent/DK2723710T3/en active
- 2012-05-29 ES ES12726067.7T patent/ES2602140T3/es active Active
- 2012-05-29 JP JP2014517549A patent/JP6116555B2/ja active Active
- 2012-05-29 CA CA2833824A patent/CA2833824C/en active Active
- 2012-05-29 US US14/115,723 patent/US9447029B2/en active Active
- 2012-06-19 TW TW101121882A patent/TWI541220B/zh active
- 2012-06-25 AR ARP120102264A patent/AR086743A1/es active IP Right Grant
-
2013
- 2013-12-02 IL IL229762A patent/IL229762A/en active IP Right Grant
-
2014
- 2014-10-07 HK HK14109983.4A patent/HK1196604A1/zh unknown
-
2016
- 2016-07-27 US US15/220,574 patent/US20160332959A1/en not_active Abandoned
- 2016-09-20 CY CY20161100931T patent/CY1118033T1/el unknown
- 2016-10-25 HR HRP20161412TT patent/HRP20161412T1/hr unknown
- 2016-11-10 SM SM201600405T patent/SMT201600405B/it unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002539193A (ja) * | 1999-03-16 | 2002-11-19 | メルク フロスト カナダ アンド カンパニー | カスパーゼ−3阻害薬としてのγ−ケト酸ジペプチド類 |
JP2009521417A (ja) * | 2005-12-22 | 2009-06-04 | ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー | カルシウム及び/又はナトリウムチャネル調節物質としての2−フェニルエチルアミノ誘導体 |
JP2010529969A (ja) * | 2007-06-15 | 2010-09-02 | ニユーロン・フアーマシユーテイカルズ・エツセ・ピー・アー | 置換2−[2−(フェニル)エチルアミノ]アルカンアミド誘導体ならびにナトリウムおよび/またはカルシウムチャネル調節剤としてのこれらの使用 |
WO2009128521A1 (ja) * | 2008-04-15 | 2009-10-22 | 帝人ファーマ株式会社 | システインプロテアーゼ阻害剤 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2019532911A (ja) * | 2017-06-20 | 2019-11-14 | ラクオリア創薬株式会社 | Nav1.7およびNav1.8遮断薬としてのアミド誘導体 |
JP2020536941A (ja) * | 2017-10-16 | 2020-12-17 | エステベ ファーマシューティカルズ, ソシエダッド アノニマEsteve Pharmaceuticals, S.A. | 疼痛及び疼痛に関連する状態を治療するためのプロパンアミン誘導体 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6116555B2 (ja) | フッ素化アリールアルキルアミノカルボキサミド誘導体 | |
JP5271087B2 (ja) | カルシウム及び/又はナトリウムチャネル調節物質としての2−フェニルエチルアミノ誘導体 | |
US9474737B2 (en) | Substituted 2-[2-(phenyl) ethylamino] alkaneamide derivatives and their use as sodium and/or calcium channel modulators | |
AU2012278193A1 (en) | Fluorinated arylalkylaminocarboxamide derivatives | |
RU2395495C2 (ru) | Производные 3-аминопирролидона | |
NZ619577B2 (en) | Fluorinated arylalkylaminocarboxamide derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150120 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150120 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20150925 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151104 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160202 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160802 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161101 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20170314 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20170321 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6116555 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |